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1.1-Gliomas and stem cells 
1.1.1-Gliomas 
Gliomas are primary diffuse infiltrating tumours of the Central Nervous 
System (CNS) that originate from glial cells. They are classified depending 
on their histological appearance and on their malignancy degree. 
Based on their origin they are classified into: astrocytomas when they 
arise from astrocytic cells; oligodendrogliomas when they originate from 
oligodendroglial cells; they can also have a mixed component of 
oligodendrocytes and astrocytes which are known as oligoastrocytomas; 
and finally there are ependydomas, constituting another type of glioma, 
most probably deriving from ependymal cells and radial glial cells (Taylor 
et al., 2005). 
Based on their degree of malignancy there are low-grade gliomas and 
high-grade gliomas (astrocytomas, oligodendrogliomas or mixed gliomas). 
Low-grade gliomas are tumours with few malignant characteristics, but 
the majority of them develop with the time (between 2 and 5 years on 
average) and end as more malignant tumours. They are classified as World 
Health Organization (WHO) grade II tumours and are diffuse infiltrating 
gliomas with a predominance of either astrocytic cells or cells resembling 
oligodendrocytes. Mixed low-grade gliomas are called oligoastrocytoma 
(WHO grade II), and in these tumours there is a mixture of cells and 
histopathological features resembling oligodendrogliomas and 
astrocytomas. 
High grade gliomas are the most frequent form of gliomas and are 
classified as anaplastic astrocytoma, anaplastic oligodendroglioma or 
anaplastic oligoastrocytoma (all of them with WHO grade III). The highest 
grade of gliomas, knowns as glioblastomas multiforme (GBM), is the most 
frequent form of them (>60%) and is called (Lantos et al., 2002, Ohgaki and 
Kleihues, 2005). They are assigned to WHO grade IV. Glioblastomas are 
frequently located in the subcortical white matter of the cerebral 
hemispheres. They can develop as “de novo” or “secondary” tumours 
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depending on their biological origin and clinical features. The “de novo” 
GBMs manifest in short time (less than three months) (Ohgaki et al., 2004) 
without precursor lesions, while “secondary GBMs” develop from lower 
grade gliomas. “De novo” glioblastomas account approximately for 90% of 
all GBM and these patients are usually older than those who develop 
“secondary glioblastomas” (Ohgaki and Kleihues, 2007). 
Histologically, GBMs are anaplastic tumours with pleomorphic cells, 
nuclear atypias, multiple mitoses (sometimes aberrant), prominent 
microvascular proliferation and necrotic zones. Glioblastomas are among 
the most vascularised tumours and their vasculature is one of the most 
important subjects in the study of gliomas (Hardee and Zagzag, 2012). 
Microvascular proliferations are a typical hallmark of glioblastomas. They 
consist of multilayered endothelial cells, even though recent research 
suggest that they consist more likely of pericyte proliferations (Girolamo et 
al., 2013), that can appear as glomeruloid tufts. 
Glioblastomas represent one of the most treatment-refractory primary 
brain tumours. Even though they are not very numerous, averaging just 
between 3-5 cases per 100.000 per year in the most developed countries 
(Lantos et al., 2002; Jovcezka et al., 2013), their mortality and mean 
survival time are indicators of this devastating disease (Ostrom et al., 
2014). The mean patient age at first glioblastoma occurrence is between 
62-64 years (Ostrom et al., 2013), but the range of incidence is between 45 
and 75 years (Ohgaki et al., 2004). Regardless of advances in surgical and 
imaging techniques, GBM remains as one of the most lethal types of 
tumour, due to their invasive growth behaviour into normal brain 
parenchyma and their resistance to standard therapies  
The treatment for GBM is surgical resection, radiotherapy and/or 
chemotherapy. Despite progress in these fields, only 20% of patients 
survive longer than one year (according to studies by Ohgaki et al., 2004; 
Ohgaki and Kleihues, 2005), even though some modern series have 
reported 29% survival rate over 2 years (Ho et al., 2014). In clinical trials the 
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mean survival time of glioblastomas is around 14 months (Ahmed, 2014) 
with radiotherapy and concomitant temozolomide. Nowadays, clinical 
trials with anti-angiogenic factors like bevacizumab (alone or in 
combination with other treatments like irinotecan) show good response in 
patients (Jovcevska et al., 2013) and improve the progression-free survival 
time (Omuro and DeAngelis, 2013), but this could be partially due to the 
fact that clinical trials tend to recruit younger patients with good quality of 
life (indicated by the Karnofsky index). 
 
1.1.2-Stem cells 
The first indications of the existence of stem cells in the brain were 
found during de 60s (Altman and Das, 1966). The distribution of stem cells 
was observed by tritiated thymidine in neonate rats in the hippocampus 
and olfactory bulb, and they were named neural stem cells. Nowadays it is 
well accepted that there are three areas in the adult brain of mammals 
which contain neural stem cells: the gyrus dentatus of the hippocampus, 
the subventricular zone (SVZ) (Eriksson et al., 1998; Doetsch et al., 1999) 
and the olfactory bulb (Lois and Alvarez-Buylla, 1994; Whitman and Greer, 
2009). 
Neural stem cells (NSC) are characterised by being undifferentiated 
cells, having the capacity to differentiate to neurons, astrocytes and 
oligodendrocytes (Alvarez-Buylla and García-Verdugo, 2002) and to 
proliferate for an extended time period. Neural stem cells also have the 
ability of self-renewal (Stem Cells: Scientific Progress and Future Research 
Directions. Department of Health and Human Services. June 2001) and can 
form neurospheres in vitro (Reynolds and Weiss, 1992). 
NSCs have the ability to infiltrate and migrate to different brain areas 
after injection in nude mice brains (Tamaki et al., 2002), and due to this, 
stem cells are being investigated for use as the basis of a therapy to  
regenerate tissue in pathologies like neurodegenerative diseases. Besides 
their promising potential to become an important tool in regenerative 
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therapy, they are also associated with tumourigenesis and invasiveness 
(Nadig, 2009). 
 
The concept of cancer stem cell (CSC) was firs reported in 1977 by 
Fidler and Kripke in melanomas. Cells of this type were experimentally 
described for the first time in leukaemia patients' blood and isolated for 
the first time in 1997 by Bonnet and Dick (Bonnet and Dick, 1997). Tumour 
stem cells, later also called tumour initiating cells because of their 
tumourigenic potential, have been defined as a subpopulation of 
neoplastic cells with characteristics  typical of somatic stem cells (self-
renewal as well as the capacity to generate all the tumour cell types). It is 
hypothesised that tumour stem cells gain these characteristics as an 
adaptation to the tumoural microenvironment, but their origin remains 
unclear. Recent research has demonstrated the relation between stem 
cells and cancer stem cells; Holland (2001) suggested that cancer stem 
cells could develop from altered stem cells. Both cellular types share the 
previously-mentioned characteristics, as well as many cell signalling 
pathways such as the Bcl-2, Sonic hedgehog (Shh) and Wnt signalling 
cascade (Reya et al., 2001). Both types of stem cells also share common 
markers like CD133, Nestin (Dahlstrand et al., 1992) and Sox2 transcription 
factor (Gangemi et al., 2009). 
Despite all the similarities between stem cells and tumour stem cells, 
there are also differences between them, such as expression of 
differentiation markers, chromosomic alterations and higher tumourigenic 
capacity of the tumour stem cells (Hadjiypanis and Van Meir, 2009). Many 
alterations that have been described can lead stem cells to cancer stem 
cell formation such as overexpresion of Notch and Akt (Takebe and Ivy, 
2010) and activation of p53 (Germano et al., 2010), among others. 
Before thediscovery of CSCs, tumour development was explained by 
the “stochastic theory”. This theory assests that all neoplastic cells are 
clones from a single cell and all of them have the same genetic alterations 
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(Hadjiypanis and Van Meir, 2009). With the discovery of the cancer stem 
cells, new hypotheses were developed such as the “hierarchical model”, 
where the stem cell status is irreversible and CSCs sustain the tumour 
growth, just like their normal tissue stem cell counterparts. Another 
difference is that in the “stochastic theory”, all the tumoural cells have the 
same tumourigenesis capacity, whereas in the “hierarchical model”, only a 
small subset of tumour cells (the cancer stem cells) are able to reproduce 
the tumour. 
Nowadays, another model is gaining traction, the “plasticity model”. 
This model assumes that only a few cancer cells have adapted to the 
tumour environment and are capable of starting the tumourigenic process 
and guide the tumoural growth (Shen et al., 2008), that is, of behaving as 
CSCs. The difference with the “stochastic model” is that the characteristics 
of stemness gained by the CSCs and the inheritability of these 
characteristics do not remain constant in the same cell population. The 
CSCs can differentiate and dedifferentiate depending on the stimuli 
produced by the tumoural microenvironment. 
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1.1.3-Cancer stem cells and glioma 
In oncology, and especially in brain gliomas, the presence of stem cells 
has been linked to bad patient prognosis. It was not until 1992 that 
Dahlstrand and collaborators (Dahlstrand et al., 1992) identified cancer 
Figure 1: Different schemes showing different theories that could explain 
the cancer growth.  
A) Stochastic theory; all the tumoural cells are clones of an original cancer 
cell. B) Hierarchical theory; one subpopulation of cells lead the tumour 
growth. The tumoural cells status is irreversible. C) Plasticity theory; the 
stemness status of the tumoural cells is reversible and depends on the 
microenvironment. 
A 
B 
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stem cells in glial tumours. As previously described, CSCs and neural stem 
cells share many characteristics, but they also show different surface 
marker expression and tumourigenic capacity. These cells could generate 
a glial tumour when injected into nude mice brains (Galli et al., 2004). 
Recent reports show that CSCs have enhanced resistance to radiation, 
thanks to more efficient DNA repair machinery via protein kinase 
phosphorilation Chk1 and Chk2. On the other hand, CSCs show resistance 
to chemotherapeutic drugs through overexpression of membrane 
transporters that pump the drugs out of the cell (Donnenberg and 
Donnenberg, 2005). 
Due to their chemo and radio resistance and their high invasiveness 
capacity, it is known that they play a pivotal role in the recurrence of glial 
tumours after therapy and they are also believed to be responsible for the 
infiltration and recurrence of glioblastomas (Schiffer et al., 2014). As a 
result, CSCs are now viewed as possible therapeutic targets. 
 
1.1.4-Cancer stem cells markers and distribution 
Despite recent efforts trying to identify the tumour stem cells, no 
specific marker has been identified so far for this cellula subtype. However, 
a wide variety of markers have been proposed to identify these cells: 
-Nestin, a protein found in neural stem cells in the SVZ, is a marker of 
neuroepithelial stemness (Jang et al., 2004). Nestin is an intermediate 
filament that is expressed in progenitor neural cells during neural 
development. In adults, Nestin is expressed mainly in the SVZ. Many 
pathologic conditions can induce Nestin to be overexpressed, like 
ischemia, inflammation or neoplasias (Holmin et al., 1997, Jang et al., 
2004). Nestin has been described as a marker of CSCs in astroglial 
tumours (Singh et al., 2003), indicating undifferentiated states and degree 
of malignancy (Schiffer et al., 2010), but it is not specific for cancer stem 
cells (Hadjipanayis and Van Meir, 2009). Nestin expression has been 
described as appearing from the first stages in glioma models (Jang et al., 
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2004) and its expression is linked to the glioma grade and has been 
observed in tumour endothelial cells, as stated in previous reports 
(Ehrmann et al., 2005). However, Nestin expression has also been reported 
in CNS after different types of injure, such as seizure, traumatic injure or 
ischemia (Schmidt-Kastner and Humpel, 2002). 
-CD133 is a transmembrane glycoprotein marker for NSCs that is 
expressed in undifferentiated cells in the early postnatal stage, and is also 
present in glioma stem cells (Dell'Albani, 2008). CD133 positive cells have 
also been observed in different types of tumour (Schiffer et al., 2010) and it 
is currently the most reliable marker for CSCs, even though there are still 
controversies about it. In gliomas, it has been described in the malignant 
stages (Christensen et al., 2008). CD133+ cells have tumourigenic capacity 
(Schiffer et al., 2010) and its expression has been related to bad prognosis 
(Zeppernick et al., 2008). 
Other markers that are not specific for stem cells but are used for the 
study of stem-like cells (in CNS tumours) are: 
-Osteopontin (OPN) is a member of the SIBLING family (Small Integrin-
Binding LIgand N-linked Glycoprotein) and is a phosphoprotein related to 
the proliferation and migration of neural stem cells (Yan et al., 2009, Kalluri 
and Dempsey, 2012). It has been associated in gliomas to a bad prognosis 
(Jang et al., 2006) and its overexpression has also been related with 
angiogenesis and parenchyma invasion (Jan et al., 2010). 
-The Notch family of transmembrane receptors comprises Notch-1, -2, 
-3 and -4. Notch signalling is essential for the maintenance of neural stem 
cells and Notch genes are widely expressed during embryonic development 
(Dell’Albani, 2008). Notch signalling has also been referred to as a 
‘‘gatekeeper against differentiation” (Artavanis-Tsakonas, 1999). Notch 
expression has been described in human tumours and tumour models 
(Jang et al., 2000) and specifically Notch-1 seems to play a critical role in 
tumourigenesis, besides of being overexpressed in human gliomas (Purow 
et al., 2005, Shih and Holland, 2006). 
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There are other markers like GFAP, Neural-tubulin, Neurofilament O4 or 
Noggin that have been linked to CSCs (Dell'Albani, 2008), but none of them 
is a specific marker. 
CSCs in tissues have been reported as being located around the 
tumoural vasculature. Calabrese and collaborators described in 2007 a 
subpopulation of Nestin positive-cells in association with the vascular 
endothelium. They also observed that cancer stem cells were found to 
secrete elevated levels of VEGF (vascular endothelial growth factor), which 
was induced by hypoxia (Calabrese et al., 2007) as it will be explained in 
paragraph 1.1.6 CSCs and hypoxia. Later, Christensen and collaborators in 
2008 described the existence of CD133+ cells around tumoural vasculature 
of human gliomas. It has been proposed that CSCs are located in “niches” 
that allow them to survive and maintain their undifferentiated status 
(Denysenko et al., 2010). Niches are defined as a limited area where stem 
cells grow, with a complex and dynamic microenvironment that regulates 
their stem cell properties (Seidel et al., 2010). 
Studies have linked this location to the chemo- and radio-resistance of 
CSCs (Denysenko et al., 2010), so the paper of these niches would be to 
provide a convenient microenvironment where the CSCs can survive and 
proliferate. The niches could serve as reservoirs where they can expand 
prior to a subsequent tissue invasion. There lies the importance of defining 
and locating these niches. 
 
1.1.5-Tumourspheres from GBM 
As there is no specific marker to identify the CSCs, the gold standard to 
identify them is the in vitro growth of tumourspheres. These appear in vitro 
under restrictive conditions, when the majority of tumour cells suffer 
apoptosis and the surviving cells grow as spheroid arrangements in 
suspension, with a rich extra-cellular matrix surrounding them. By 
definition, stem cells have the capacity to give rise to spheres when grown 
in specific conditions. If the neurospheres are then dissociated into single 
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cells, these cells can give rise to secondary neurospheres, and soproducing 
neurospheres in a serial fashion and hence demonstrating their self-
renewal properties (Das et al., 2008). It is also known that tumourspheres 
are formed from various statuses of differentiated and undifferentiated 
cells (Ahmed, 2009); the stem cells and their different status differentiated 
progeny. This fact complicates even more the identification of cancer stem 
cells. Cells from the tumourspheres show positivity for many stem cell 
markers such as CD133, Nestin, GFAP, Sox-2 etc. (Pastrana et al., 2011) 
(Fig. 2). 
Nowadays the sphere-assay is considered as an experiment that 
evaluates the potential to behave like a stem cell. 
 
1.1.6-CSCs and hypoxia 
It has been reported that the tumour microenvironment is essential for 
the survival and genesis of the cancer stem cells. Cancer stem cells have 
also been described as the cellular subpopulation with the capacity to 
regenerate the tumour inside a suitable environment (Fan et al., 2007). 
When gliomas become malignant, neoplastic cells increase metabolic 
requirements, being supplied by microvascular adjustments. However, at 
some point, tumoural requirements exceed the metabolic support of these 
adaptive changes of the pre-existed microvasculature and the genesis of 
new vessels is induced to supply oxygen and nutrients. When the 
Figure 2: Morphology of neurospheres and immunocharacterization with 
stemness markers. Adapted from Scully et al., 2012. 
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microvascular network is not able to provide enough oxygen, tissues suffer 
hypoxia. Microvascular alterations develop in malignant tumours as a 
result of an adaptive process to the referred relative tissue hypoxia. One of 
the most important consequences is the compromise of the Blood-Brain 
Barrier (BBB) function. 
Hypoxia is a typical feature of GBM. It has been reported that hypoxia 
induces the selection of clones of tumoural cells. Some of these cells 
would suffer adaptations in order to survive, transforming themselves into 
tumoural stem cells (Heddelston et al., 2009). When hypoxia appears, 
hypoxia-induced factor (HIF) is activated and its expression induces the 
up-regulation of different molecules like VEGF (linked to angiogenesis), 
iNOS (Inducible nitric oxide synthase; related to vasodilation), EPO 
(Erythropoietin; a key molecule activating the erithropoiesis) and TGF-beta 
(Transforming growth factor; increasing cell proliferation) (Fig. 3). 
Oxygen concentration also seems to be a key factor in the apparition 
and maintenance of the stemness state. Hypoxia would transform these 
cells, providing them with a higher proliferation rate, more angiogenesis 
capacity (Bao et al., 2006 b) and higher tumourigenesis (Heddelston et al., 
2010). This step could be activated by the expression of some genes like 
Notch or Sox2, which have been found in vitro to be overexpressed in 
hypoxic cells (Gustafsson et al., 2005). 
Hypoxia enhances CSC characteristics, increasing CSC proliferation in 
cultures (Pistollato et al., 2010), as well as inducing HIF-2α overexpression 
in CSC (Heddleston et al., 2009). Hypoxia induces the expression of HIF-2α, 
but it does not increase HIF-1α expression in neurospheres. Moreover 
hypoxic conditions in vitro induced an increase in Nestin and CD133 
(Kolenda et al., 2010). HIF-2α expression could induce the stem cell 
phenotype by inducing non-stem cells to transform into stem cells and 
increasing stem cell proliferation (Heddleston et al., 2009). This hypothesis 
was later confirmed by the appearance of CD133 positive cells under 
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hypoxic conditions, reverting to a more differentiated condition when 
normoxia was applied (Griguer et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A relationship has been described in human glioblastomas between the 
appearance of the tumour stem cell phenotype and intratumoural oxygen 
gradient (Pistollato et al., 2010). According to this research, oxygen 
concentration is a lead factor in cancer stem cell dedifferentiation (Fig. 4). 
Cancer stem cells have been identified in perinecrotic pseudopalisades, 
typical of glioblastoma multiforme (Jang et al., 2006; Jensen, 2006). The 
cells around the pseudopalisades were also found to express HIF-1α (Kaur 
et al., 2005), so further research into whether this hypoxic cells are cancer 
stem cells would be needed, to study whether the hypoxic cells adapt to 
the hypoxic conditions by undifferentiation. 
Figure 3: Angiogenesis regulation via HIF-cascade. Adapted from Loser et 
al., 2010. 
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It is believed that CSCs activate the HIF/VEGF pathway (Bao et al., 2006b), 
thus implying that CSCs are related to the angiogenesis process. 
 
 
1.1.7-CSCs and angiogenesis 
Angiogenesis is the process of building new vessels from the pre-
existing ones, and is vital in many tumours, especially in gliomas. The 
angiogenesis process also regulates the tumoural progression and it is 
mainly regulated by VEGF (among other factors). 
VEGF is a proangiogenic and permeability factor that has many 
functions in physiologic (Kamat et al., 1995) and pathologic angiogenesis 
(Folkman, 1995, Dvorak, 2006), regulating the tumoural neoangiogenesis 
(Dvorak 2007). VEGF permeabilises the vascular wall (Dvorak, 2006) by 
producing endothelial fenestrations, which the brain normally lacks. 
Alteration of the morphological substrate of the Blood-Brain Barrier 
produces cerebral oedema, an epiphenomenon that is the major cause of 
death in patients with brain tumours (Bulnes et al., 2010). 
As previously stated, CSCs have beenreported in vivo to be located 
around the tumoural vasculature forming the perivascular niche. Yang and 
Wechsler (2007) also stated that the perivascular niche of glioma stem 
cells could mediate in tumoural vascular adaptation. They found plenty of 
CSCs around the abnormal tumour vasculature and suggested that glioma 
HIF 
Notch 
Tumoral 
cell 
CSC 
 
[O2] 
Migration 
 
Tumorigenesis 
 
Chemoresistance 
Figure 4: Scheme of the adaptations that suffer the CSCs to survive to 
hypoxia and the characteristics that acquire. 
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stem cells enhance vascular niche development through secretion of 
proangiogenic factors, such as VEGF. Recently, VEGF has been described 
as inducing the tumourigenesis of cancer stem cells (Li et al., 2009), 
confirming the tight link between CSCs and angiogenic factors. 
Accordingly, it is supposed that CSCs in the perivascular niches induce 
angiogenesis mediated by VEGF, contributing to the regulation of hte niche 
microenvironment. 
CD133+ cells had been previously found to express VEGF and to 
promote angiogenesis after being injected into nude mice (Bao et al., 
2006b). In addition, CD133+ cells activate endothelial cells to increase the 
expression of proangiogenic factors expression (Folkins et al., 2009). 
Recently, relation between CSC and the microvasculature has been 
studied the, suggesting that microvessels contribute to creating and 
maintaining a niche microenvironment where CSCs can grow (Calabrese et 
al., 2007). Following this hypothesis, Borovski and collaborators (2009) 
reported that CSCs in culture have a higher proliferation rate when cultured 
with microvascular endothelial cells rather than alone. This study also 
suggested that this effect is not only due to soluble factors such as VEGF, 
PDGF… implying that these niches are composed by a combination of stem 
cells, differentiated cells and endothelial cells. Other studies suggest the 
possibility of cellular transdifferentiation of CSCs into endothelial cells as 
part of the neoangiogenesis (Soda et al., 2011, Scully et al., 2012), but this 
hypothesis still needs further research. 
Since the proliferation and invasion of adjacent normal parenchyma 
has been attributed to glioma stem cells, it is believed that these cells use 
the extracellular matrix of the vessel wall as a migration pathway to 
infiltrate normal brain parenchyma, so the CSCs also rely on the 
vasculature to migrate. 
 
 
 
                                                                                                           Introduction 
 - 17 - 
1.1.8-Future of CSCs in therapy 
Conventional anticancer therapy includes therapies that are 
predominantly targeted against the whole fast-dividing tumoural cell 
population. Only a few therapies are targeted directly against tumoural 
characteristics, as is the case of antiangiogenic therapies. 
Nowadays, there is an increase in the study of treatments against CSCs 
(Fig. 5), which mediate the invasiveness and tumourigenesis, but targeting 
CSCs in vivo is very difficult, because the immunomarkers to identify them 
are not well defined yet and the stemness status is subject to change due 
to the microenvironment (Hadjypanis and van Meir, 2009). However, these 
therapies could be doomed to failure, due to the fact that CSC status is not 
a permanent status (as previously believed), but a consequence of the 
adaptation of some cells to adverse conditions. So, after therapy against 
undifferentiated cells, they could simply adapt themselves to a more 
differentiated status in order to avoid these treatments. 
Ideally, the best way to target CSCs would be to attack them when they 
are identifiable and to block the pathways that induce the dedifferentiation. 
Some approaches have been made in vitro and in vivo in order to target the 
CSCs. For example, Bao and collaborators in 2008 used the L1CAM (cell 
adhesion molecule L1), which is preferentially expressed in CD133+ 
gliomas, to target these cells. They showed that a shRNA-mediated 
knockdown of L1CAM reduces the neurosphere-forming capacities of 
CD133+ cells and selectively induced apoptosis of CD133+ cells, but not 
CD133- cells. In vivo L1CAM knockdown showed prolonged survival after 
tumour xenografts. 
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2.-Animal models for gliomas 
 
1.2.-Animal models for glioma 
The clinical importance of gliomas urged a search for a reliable model 
that could mimic all the characteristics present in human gliomas. As 
stated by Candolfi and collaborators in 2007 (Candolfi et al., 2007), a 
perfect glioma model should grow in vivo with predictable and reproducible 
growth patterns, should have close resemblance to the histopathology of 
human gliomas, be weakly or non-immunogenic and its progression 
should be highly reproducible. 
 
Figure 5: Possible pathways that could be targeted in future anti-CSCs 
therapies. Adapted from Frank et al., 2010. 
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The first animal models of gliomas date from the 1960s as ENU (Ethyl-
Nitrosourea)-induced rat models (Druckrey et al., 1966), but lately, murine 
xenograft models (either intracerebral or subcutaneous) and genetically 
engineered mouse lines have increasingly been used (Chen et al., 2013) 
(Fig. 6). 
 
Rat glioma models show advantages over mice models, such as larger 
brain and larger glioma size at death, which are easier to detect with 
imaging techniques (Barth and Kaur, 2009). On the other hand, rat glioma 
models also have disadvantages as compared to mouse models; e.g., it is 
more difficult to genetically engineer them (with all the implications that 
this has; genetic/proteic factors, pathways…) and they are more expensive. 
To date, the following models are most frequently used to mimic 
gliomas in animals: 
-Xenograft models: The inoculation of established cancer cell lines into 
mice. 
These models suffer from a lack of a regular immune system, thereby 
not accurately representing the cellular composition of the original tumour 
as well as a lack of histologically-similar vasculature (Finkelstein et al., 
1994). The main advantages of this model are the high reproducibility, fast 
Figure 6: Graph with the published papers in the last 20 years that included 
“ENU” (White) or “xenograft GBM” (black). Data acquired from Pubmed. 
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tumour development (Fomchenko and Holland, 2006) and the accurate 
knowledge of the location of the tumour (King et al., 2005).  The injection of 
tumour cells can be performed subcutaneously or directly into the brain 
(orthotopical).  Nowadays, it is the most popular method for producing 
CNS tumours, because the gliomas develp in a short time, it is relatively 
inexpensive and easy to perform, and established glioma cell lines are 
readily available. 
-Genetically engineered mice: These are more representative of human 
cancer syndromes, rather than primary tumours, because of their origin. 
They are created to express oncogenes or suppress anti-oncogenes 
(Janbazian et al., 2014). There are numerous examples, like altering 
specific signalling pathways such as Ras/Akt (EGFR) or mutating genes 
like v-src, v-erbB or p53 (Fomchenko and Holland, 2006). The advantages 
of this model are the possibility of creating conditioned models of the 
tumour initiating lesions and immunocompetence of the mice (and so 
being able to control the start of the mutation). However, there are many 
disadvantages such as poor reproducibility, low tumour penetrance, and 
high latency (Fomchenko and Holland, 2006). 
-Oncogenic virus inoculation: There are some cancer cell lines that are 
produced from the inoculation of oncogenic virus in mice. The most used 
virus is the avian sarcoma virus (Barth and Kaur, 2009). 
-Administration of chemical substances: The exposure to chemical 
compounds to produce CNS tumours has been performed since the 60s 
(Druckrey et al., 1966). Methyl-nitrosourea and N-Ethyl-N-nitrosourea are 
two compounds that have proven to be tumourigenic (Bosch, 1977). They 
provide tumours histologically similar to human tumours (Fomchenko and 
Holland, 2006), but take a long time to develop (Zook and Simmens, 2005). 
The endogenous generation of gliomas via transplacentary injection of 
ENU in rats during pregnancy has been widely documented and is a well-
known and reliable model to study gliomas in different stages (Zook and 
Simmens, 2005; Bulnes-Sesma et al., 2006). It also provides a tumour with 
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the hots’s own cells, where the tumoural vasculature develops at the same 
time that the gliomas become malignant. 
It is important to realize that despite all accumulated experience with 
the aforementioned models, no currently available animal tumour model 
exactly simulates human high-grade brain tumours such as glioblastoma 
or anaplastic astrocytomas. 
 
1.2.1-ENU-induced glioma model 
The ENU-induced glioma model provides endogenous gliomas that 
evolve from the smallest stages to the most malignant. It has been 
suggested that the long latency of the ENU-induced gliomas is due to the 
mechanism of generation of these tumours, in which (like spontaneous 
tumours) many mutations have to accumulate until the tumours develop 
(Schiffer et al., 2010). 
ENU is a powerful mutagenic agent that alkylates DNA; more precisely 
it alkylates the O6 in the guanine and the O2 in the thiamine. ENU 
preferentially alters AT base pairs. GC-rich genes will not be mutated as 
often as those with a lower GC content. Similarly, the size of the gene will 
also affect the rate at which it will be mutated i.e. larger genes will provide 
a larger target for random mutagenesis than a smaller one (Kennedy and 
O`Brian, 2006). 
It has been reported that ENU generates a T:A---A:T transversion and a 
G:C---T:A transition, and this has been largely studied (Jansen et al., 1994), 
but it produces mainly the transversion effect (44%), rather than the 
transition effect (38%). Additionally, it also produces small deletions 
(Slikker et al., 2004). ENU effectively induces point mutations in a genome-
wide manner, which resembles most of the causes of human genetic 
diseases (Gondo and Fukumura, 2009). The accumulation of these 
successive alterations seems to be responsible for the effect of ENU in the 
expression of multiple genes like p53, neu/erbB-2, Osteopontin, p21 and 
cyclin G1, which become up-regulated (Katayama et al., 2005). The 
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consequences of these alterations are the development of CNS tumours. 
The range of these tumours is from brain tumours (which are 
oligodendrogliomas, astrocytomas or mixed gliomas of all degrees of 
malignancy) to cranial nerve tumours (mainly schwannomas from 
trigeminal nerves) and spinal cord tumours (Zook and Simmens, 2005). 
Oligodendrogliomas and mixed gliomas are the most common tumours 
after the ENU administration (Zook et al., 2000). It has been proposed that 
the majority of the brain tumours begin as oligodendroglial tumours and as 
they become more malignant they develop an astrocytic component, 
transforming the tumours into mixed gliomas (Zook and Simmens, 2005). 
Histopathologically, the brain tumours have all the typical characteristics 
of the human gliomas, like necrosis, haemorrhages, microvascular 
endothelial proliferation, atypical mitoses, cellular anaplasia (Zook et al., 
2000; Bulnes-Sesma et al., 2006). 
Prenatal exposure to ENU has also proven to produce cell cycle 
alterations in neural stem cells around the subventricular zone (Capilla-
Gonzalez et al., 2012) and to reduce the amount of stem cells in the SVZ 
(Capilla-Gonzalez et al., 2010). It has been suggested that the neural 
precursors of the SVZ are mutated after ENU administration (Gil-Perotin et 
al., 2006). However, it is not known yet if these alterations have any 
implications in the carcinogenesis process after ENU administration. 
Due to its potent mutagenic potential, ENU has been also used to 
induce genome-wide point mutations in mice (Gondo et al., 2010) and in 
rats (Huang et al., 2011), in order to phenotypically identify the causing 
genes by forward genetics (Gondo et al., 2010). In these projects, male 
mice are injected with ENU and as a result, germline mutations are induced 
in spermatogonia that are inherited after mating with female mice. The 
detected phenotypical alterations inherited by the newborn mice are all 
heterozygous, therefore the mutations are dominant. Nowadays, there are 
more than 10000 samples with over 3000 mutations each archived by 
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international projects like RGDMS (RIKEN-ENU based Gene-driven 
Mutagenesis system), KOMP, EUCOMM (Gondo et al., 2010). 
 
1.3-Clinical diagnosis 
In the same way as in humans, experimental model of gliomas do not 
show symptoms until the tumours are in an advanced stage of 
development. The main problem with animal models is that animals 
cannot be asked about their health, so other methods had to be developed. 
Rodent animal models also have the inconvenience that it is difficult to 
detect clinical symptoms associated with sickness, as diagnostic methods 
are not refined enough. 
 
1.3.1-Animal welfare 
Animals cannot tell actively if they are suffering pain, or have physical 
discomfort. A baseline of welfare has to be established for the animals, as 
well as precise methods that can discern as soon as possible when the 
animals become unhealthy. 
In order to decrease pain and detect the lack of welfare as soon as it 
happens, new methods to detect early changes in the animal’s behaviour 
should be developed. 
Animal welfare is defined as an animal when it is healthy, comfortable, 
well nourished, safe, able to express innate behaviour, and it is not 
suffering from unpleasant states such as pain, fear or distress. 
Aanimal welfare requires disease prevention, veterinary treatment, 
appropriate shelter, management, nutrition, human handling and human 
slaughter. 
Another way to define animal welfare is the Five Freedoms (Farm 
animal welfare committee). These Five Freedoms include: 
-Freedom from hunger or thirst by ready access to fresh water and a 
diet to maintain full health and vigour. 
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-Freedom from discomfort by providing an appropriate environment 
including shelter and a comfortable resting area. 
-Freedom from pain, injury or disease by prevention or rapid diagnosis 
and treatment. 
-Freedom to express (most) normal behaviour by providing sufficient 
space, proper facilities and company of the animal's own kind. 
-Freedom from fear and distress. 
Animal welfare also includes the handling of the animal by the 
experimenters, who must be kind and be conveniently prepared in the 
animal’s handling. 
 
There are three main methods to perform clinical diagnosis for any 
pathology; 1.-subjective tests that depend on handling and observation by 
the investigators, 2.-objective tests (carried out by devices) and 3.-
complete monitoring of animal parameters in a controlled environment 
simulating their home. The advantages and disadvantages of these 
methods are the discussed below. 
For many years, clinical diagnosis relied on non-standardised 
subjective protocols and tests, including human manipulation and 
observation. Direct handling by the experimenters has been proven to be 
very unreliable, due to the fact that experimenters influence the outcome of 
the tests, and are a source of variation in results (Chesler et al., 2002). An 
example of these tests is the “welfare status” performed by Morton & 
Griffith (1985). 
On the other hand, objective tests, mimicking clinical probes, were 
performed in order to achieve a clinical diagnosis. Available probes are 
based on brief trials in standardised system like the “open-field” test, 
which was first developed for anxiety detection (Denenberg, 1969). These 
tests are carried out in a specific bounded time. It is important to note that 
these systems are well standardised for some uses (such as anxiety, as 
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previously mentioned), but it can lead to difficulties in replication of the 
results when applied to different situations (Mandillo et al., 2008). 
In order to objectify clinical diagnosis, appropriate current methods 
include the automatic monitoring of the animal’s food and water intake, 
study of its physical state, monitoring its capacity of movement…, in a 
controlled area. This system has been called “homecage”. The first 
homecage systems began to be used in the 90s (Saibaba et al., 1996) in 
order to monitor animal behaviour with minimal human interference. 
The only disadvantage of these systems is the increased time that has 
to be used in the tests, consuming for a couple of hours a day during 
several days or weeks. In the future, these methods will replace the classic 
diagnosis because they are cheaper and, after its standardization, they are 
also easier. 
Behavioural changes happen almost in every disease in human and 
animal models, and chronic diseases are the best models to study 
behavioural changes in rats, because the changes happen slowly and at 
some point, it is presumable that behavioural changes appear before the 
animals externalise the discomfort or pain. 
In the last decade, behavioural clinical diagnosis has been gaining 
weight in efforts to find an early and cheap diagnostic method, prevent 
animal pain and distress, learn more about the initial stages of diverse 
diseases and phenotypically characterise mice and rats mutant strains 
(Mandillo et al., 2008). 
Those systems have a standardised environment and methods, 
offering a similar environment to the natural state, and as the data is 
collected by computer equipment, behavioural data is gathered objectively 
(Clemens et al., 2014). Unfortunately, as of now, there is little literature 
regarding animal behaviour in homecage systems, which makes it more 
difficult to use these methods for diagnosis in the animal models. 
Historically, these tests have been used as a diagnostic tool in models 
for psychiatric diseases, but not in models that represent chronic and 
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mortal diseases such as cancer. Not even in humans are there many 
studies about gliomas and behaviour, apart from a few about gliomas and 
depression (Starkweather et al., 2011). 
The principle of homecage systems is to maintain the animals in a 
familiar, stress-reduced environment. (TSE-systems. Available at 
http://www.tse-systems.com/products/behavior/home-
cage/phenomaster/index.htm). These systems have many advantages: 
data can be measured for a determined time, be it from minutes to days, 
and collected data can be split into time-intervals if wanted (e.g.: only at 
night, only at day, the first/last “x” hours...). They reduce the handling and 
transportation of the animals (limiting stress levels and avoiding variables) 
and optimise the use of animals (Noldus. Available at 
http://www.noldus.com/content-view/home-cage-monitoring-system). 
The modular design of homecage systems also allows a wide range of 
experimental procedures for characterising the evolution of the animal’s 
behaviour during the experimental process (Panlab. Available at 
http://www.panlab.com/en/products/phecomp-system-panlab). 
With homecage systems, the assessment of behaviour takes place in a 
fully–automated manner in the experimental animal`s own environment 
(Neurobsik. Available at http://www.neurobsik.nl/Homecageasses.html). 
Homecage systems can also provide standardised protocols that are easily 
reproducible, without external variables. 
Natural animal behaviour is a relatively unstudied area, and even more 
so when it is related to physical diseases. Housing and testing animals in 
homecage environments helps with the animal welfare awareness and 
fulfilment. 
With the help of these systems to identify early alterations in the 
behaviour and activity patterns of the rat, it is easier to detect pathologies 
before the animals acquire severe physical handicaps, thus improving their 
animal welfare. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II.-Hypothesis 
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Some cancer stem cells are responsible for the origin, maintenance 
and growth of gliomas. Despite studies about their functions, little is 
known about the differential distribution in various degrees of malignancy 
degrees, their participation in the early stages and their role in glioma 
development. The main hypothesis of this study is that the identification of 
cells expressing several stemness markers in early and advanced stages 
of gliomas may be useful to understand their development and 
progression, and eventually to design treatments against this neoplasia. 
 
The ENU-glioma model is very useful to study morphological and 
molecular characteristics of cells expressing stem cell markers and, in 
addition, it also allows the study of clinical changes following the initial 
apparition of the gliomas. Clinical symptoms in rats with glioma appear 
quite late, when the pathology is in an advanced stage, hence the necessity 
of designing a method to identify these early changes. An early diagnostic 
suspicion based on behavioural changes such as movement, feeding, 
exploration, rearings (standing on rear limbs) and so on provides an easy 
method to unveil the initial phase of the tumour, and constitutes an 
indication to perform advanced imaging techniques, such as Magnetic 
Resonance Imaging (MRI). An adequate monitoring of vital constants and 
animal behaviour is a very useful and required tool to reduce pain or 
discomfort and to increase animal welfare in experimental research. 
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3.1.-Main objectives 
Identify and locate Nestin-positive cells in an endogenous model of 
gliomas, from early to advanced stages, reporting their distribution in 
different tumoural areas and their co-expression with other stemness 
markers. 
Establish a clinical protocol identifying physical and behavioural 
changes in order to obtain indirect evidences of tumour development 
before clinical symptoms are visible. 
 
3.2.-Procedural objectives 
1.-Monitor clinical and behavioural variables in rats prenatally exposed to 
ENU with a homecage system and the open-field test searching for clinical 
symptoms that suggest the apparition of a pathology. 
 
2.-Detect the induced brain gliomas and classify them in different stages 
via MRI and histopathological study. 
 
3.-Study the morphology and distribution of Nestin-positive cells inside 
experimental gliomas, mapping their distribution in different stages of 
glioma development. 
 
4.-Analyse the co-expression of Nestin-positive cells with other stemness 
markers: OPN, Notch-1 and CD133 in different ENU-glioma stages. 
 
5.-Immunophenotypical characterization and morphometrical analysis of 
Nestin+ cell arrangements in perivascular areas and inside gliomas at 
different stages of development. 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IV.-Material and Methods 
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4.1-Tumour induction 
For the present study, 94 offspring born from 10 ENU-injected 
Sprague-Dawley rats were used for the studies described in Table 1. From 
the 94 offspring rats, 36 were used for the behavioural study, 24 for the 
proliferation study and 13 for the MRI study. After their sacrifice, all of 
them, including the remaining ones, were used for the 
immunohistochemical study against stemness markers in the 91 gliomas 
that were identified.  
The tumour induction was made by a single ENU (N-Ethyl-N-
nitrosourea; Sigma E2129) injection in the 15th day of pregnancy. ENU was 
diluted at 10mg/ml in 0.9% NaCl and the solution intraperitoneally injected 
at 80mg/kg of body weight. For this purpose rats were slightly 
anaesthetised with isofluorane 2% (IsoFlo, Veterinaria Esteve, 1385 ESP). 
 
10 pregnant 
rats 
94 offspring rats 
91 
gliomas 
Immunohistochemistry 
 -36 behaviour  Quantification 
 
-24 proliferation 
study 
  
 -13 MRI   
 
Animals were bred in standard housing conditions and food and water 
were available ad libitum. All animal experiments were performed in 
accordance with Spanish Royal Decree 1201/2005, Directive 2003/65/EC 
of the European directive 2003/65/CEParliament and the EU 
Recommendation 2007/526/CE about experimental animal EC regarding 
the protection of animals used for purposes. 
 
Table 1: Scheme of the number of rats used for each study and the number 
of gliomas developed by all ENU-exposed rats. 
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4.2-Tumour screening 
Tumours were detected by clinical symptoms, behavioural anomalies, 
MRI imaging and after the autopsy by macroscopic and histopathological 
study. 
The behavioural evaluation was performed on 36 rats (15 male and 21 
female) during the ENU-glioma development from the 4th to the 8th month 
of age and 8 normal rats were used as controls (4 male and 4 female) of 
the same age. Males and females were segregated because of the big 
differences in the studied parameters. This evaluation consisted in 3 
studies: 1.- the welfare score according to a modified version of Morton & 
Griffiths table (1985) (this test was performed just before they entered the 
Phecomp cage), 2.- a continued monitoring of the parameters listed below 
in a homecage system (Phecomp), (this was performed once every four 
weeks) 3.- application of the open-field test once every four weeks. 
The parameters studied in the homecage system were: food and water 
intake, % of time moving, number of rearings (every time the rat stands on 
its rear limbs), total distance walked, and % of exploration in the first 4 
hours (defined as the time the rat was exploring the central area of the 
cage in the first 4 hours). The parameters studied in the open-field test 
were % of time moving, number or rearings, total walked distance and % of 
exploration (defined as the time the rat was exploring the central area of 
the cage/the total time of the test). 
 
4.2.1-Monitoring of the animal welfare 
Animals injected with ENU were analysed every two days to establish 
their health status, taking into account abnormal postures, abnormal 
vocalisations or unusual weight loss, extreme immobility or swollen eyes. 
The welfare of the rats was studied with an adaptation of the Morton & 
Griffith (1985) table for animal well-being (Table 2). 
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Parameter Status Score 
Weight loss 
No loss 
≤ 10% 
≥10 ≤20% 
≥ 20% 
0 
1 
2 
3 
Aspect 
Normal 
Fur in bad conditions 
Fur in bad conditions and/or 
nasal or ocular secretions 
Abnormal posture 
0 
1 
2 
 
3 
Spontaneous 
behaviour 
Normal 
Small changes 
Inactivity 
Auto-mutilation, abnormal 
vocalisations, immobile or 
agitated animal 
0 
1 
2 
3 
Induced 
behaviour 
Normal 
Small changes 
Medium changes 
Comatose or aggressive 
animal 
0 
1 
2 
3 
 
This test was always performed by the same person, in order to reduce 
the variability. To obtain the total score, one status of each parameter has 
to be selected (the one more suitable for the animal) and then each 
parameter score has to be summed up. 
If two or more categories have a score of “3”, all scores of “3” change 
to a score of “4”. 
Total score ranges from 0 to 16 and it is interpreted in the following 
way. 
 0-3: normal 
 4-7: supervision 
 8-12: extrasupervision and/or considering sacrifice 
 13-16: sacrifice; dangerous procedure 
Table 2: Modified table score for the animal welfare. Adapted from Morton & 
Griffith (1985). In terms of the spontaneous behaviour, we have defined 
small changes as an increase in the grooming activity of their head and 
forepaws or not forming a bed or a specific area for self-hygiene. In the 
induced behaviour we have defined small changes as trying to hide more 
than usual and medium changes include exaggerated escape behaviour. 
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4.2.2-Homecage system 
This study consists in a 48-hours stay in a controlled environment in a 
homecage system called a Phecomp cage (Panlab, Barcelona, Spain; Fig. 
7). The device consists of a cage (Allentown Caging Equipment, ACE, 
197W×306D×212H mm) provided with a grid floor. The cage is associated 
with one external unit for food and one for drink recording. The system 
records the food cosumed and the quantity of water drunk. A built-in 
display allows following in real-time the evolution of the total amount of 
food and drink consumption during the experiment. Animal horizontal 
activity is recorded by means of two infrared frames and rearings with two 
infrared frames at a height of 13 cm. We only counted the data from the 
two nocturnal periods (two periods of 12 hours each), when the rats are 
active. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Phecomp cage above the registering unit. There is one unit for 
water and another for food and two frames (constituted by photoelectric cell 
and infrared beams) that detect the position of the animal and the rearings. 
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Once all the rats had gone through the tests, these started again; so 
providing continuous testing. There is a decrease in the number of rats 
every time, because they were sacrificed when they showed severe 
physical handicaps. So the 80 experimental tests and the 48 control tests 
correspond to the following distribution:     
ENU-group  Control group 
-4 months:   36 rats   8 rats 
-5 months:   23 rats   8 rats 
-6 months:   10 rats   8 rats 
-7 months:   4 rats   8 rats 
-7.5 months:   4 rats   8 rats 
-8 months:   3 rats   8 rats 
   Total: 80 test   48 tests: 128 tests 
 
4.2.3-Open-field test 
This test was performed using a photoelectric actimeter (Actitrack, 
Panlab, S.L., Barcelona, Spain; Fig. 8). The apparatus consisted of a 
transparent cage of 45 cm x 45 cm with a central area predetermined to 
measure 24 cm x 24 cm. The cage is connected to a photoelectric cell and 
locomotor activity was detected by infrared beams, with an infrafred frame 
at a height of 13 cm to detect rearings. All testing in the actimeter was 
done during 5 minutes in an isolated room between 16:00 and 17:00 hours, 
right after finishing the homecage test. 
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All the behavioural data was automatically collected and interpreted 
with Compulse 1.1 (Panlab, Barcelona, Spain) and Actitrack 2.7.13 
software (Panlab, Barcelona, Spain) (Fig. 9). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Image of the openfield cage, linked to the registering unit. 
Surrounding the cage there can be seen the two infrared frames that 
determine the position and activity of the rat during the test. On the right 
there is a representation of the rat and the two areas predetermined by the 
experimenter as the external and internal areas. 
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4.3-Magnetic resonance imaging study 
13 rats were selected for MRI study when they reached the 5th month 
(7 rats) and 6th month (6 rats) of life (MRI, Biospec BMT 47/40, Bruker, 
Ettlingen, Germany, operating at 4.7 Tesla in the CAI (Research Support 
Centre) of the Complutense University of Madrid, Fig. 10). In order to scan 
the brain, animals were anaesthetised with isofluorane and 
Figure 9: Screen captures of Compulse (up) and Actitrack (down) software 
to analyse the data collected with the Phecomp cage and Open-field test. 
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intraperitoneally injected with 1.5 ml/kg.body weight of gadolinium (Gd-
DTPA, Magnevist, Schering AG, Berlin, Germany). Coronal and sagital 
images on T2-w fast spin-echo (TR/ effective TE= 3000/60 ms) and on 
T1-w spin-echo sequence (TR/TE = 700/15 ms) were obtained 
immediately after contrast administration. 
MRI is based on the movement of the hydrogen protons of the tissue, 
motivated by the variations in the magnetic field induced by radio 
frequency pulses. T1 and T2 are different relaxing times of the protons, T1 
being the longitudinal relaxing time, and T2 the time the protons take to 
disorganise. 
 
 
 
 
 
 
 
 
 
 
 
4.4-Proliferation assay 
BromodeoxyUridine (BrdU) was used to study the cell proliferation. For 
this purpose 80mg/kg body weight of BrdU (Sigma-Aldrich; B5002), 
diluted in NaCl 0.9%, was injected intraperitoneally to 24 rats three times 
at intervals of three hoys. One hour after the last injection, animals were 
sacrificed by perfusing them with PFA 2% and the tissue was processed 
for histological examination. 
Figure 10: Image of the MRI device used for the tumour detection. Device 
located in the CAI of Universidad Complutense de Madrid. 
                                                                                         Material and methods 
 - 45 - 
4.5-Tissue processing 
The rats were sacrificed when they showed deficits that could threaten 
their life or when they reached a score of 11 or more in our adapted 
Morton & Griffiths table (meaning they had a critical health status and had 
lost their welfare) or when a tumoural mass was observed in the MRI 
images. 94 rats were anaesthetised by intraperitoneal injection of chloral 
hydrate at 10% and transcardially perfused with a 0.9% NaCl solution, 
following with 4% paraformaldehyde (Panreac; ref: 141541.1211) in PBS 
0,1M (pH=7.4). 
Afterwards, the brains were removed and postfixed by placing them in 
a 4% PFA solution at 4ºC overnight. Medulla was extracted when visible 
symptoms of mobility incapacity were appreciated. The next day, the 
brains were washed with PBS 0.1M and cut into coronal sections. The 
coronal sections were used in two different protocols: 
a) Some sections were embedded in paraffin like following: 
• Brain section are placed in unicasettes and placed overnight in 
alcohol 50º. 
• The brains are placed in two baths of ethanol 50º for two hours. 
• Two baths of alcohol 70º of two hours. 
• Overnight immersion in ethanol 96º (ENMA; ref: 190). 
• Two baths of ethanol 100º (ENMA; ref: 180) for two hours. 
• Three baths of 90 minutes in chloroform (JT Bajer; ref: RS69387). 
• One bath of 30 minutes in a mixture of xylene/paraffin 50%. 
• The brains are kept overnight in paraffin (Histosec; Merck; 
ref.:11609) at  
        56º C. 
• One bath of paraffin at 56º C. 
• Create the blocks using moulds and a paraffin dispenser (MYR 
EC350-1; EC351.0349). 
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• Finally the sections embedded in paraffin were cut with a 
microtome (Microm: ref: HM-440-E) at 4 μm. 
b) Other sections were stored one day in a 30% sucrose (Panreac 
Química ref: 131621) solution in PBS 0.1M at 4ºC. The sucrose 
solution is used to prevent the formation of crystals in the tissue while 
the freezing. Then the sections were cut with a cryotome at -25ºC and 
50 μm thickness. The slices were kept in a 0,5% azide (Sigma-Aldrich, 
ref:S-2002 ) solution in PBS 0.1M. 
 
4.6-Histopathological study 
We used some 4 μm thick sections obtained by microtomy (Anglia, 
Type 200) for the Hematoxylin/Eosin staining to detect and classify the 
tumours according to histopathological features such as haemorrhages, 
cysts, cellular anaplasia, nuclear atypias, high mitosis and vascular 
proliferations. 
Hematoxylin/Eosin staining was performed as follows: 
• Deparaffination by two baths of 10 minutes in xylene (Panreac; 
ref:211679.174). 
• Hydration of the sections by immersion in decreasing gradient 
alcohols every 5 minutes in 100º, 96º, 80º, 70º, 50º and distilled 
water. 
• Immersion in Harris Hematoxylin for 2 minutes. 
• Wash with distilled water. 
• Differentiation in 0.5% HCl (Panreac Química ref:131020.1611) in 
100º ethanol for two seconds. 
• Wash in tap water for a couple of seconds. 
• Immersion in Eosin for 20 seconds. 
• Dehydration by immersion in increasing gradient ethanol every 5 
minutes in 70º, 80º, 96º, 100º, 100º. 
• Two immersions in xylene for 5 minutes. 
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• Protection with cover-slides using DPX resin (Sigma-Aldrich, ref.: 
44581). 
 
4.7-Lectin histochemistry 
Lectins are vegetal glycoproteins with the capacity to bind selectively 
to foreign glycoconjugates. Many lectins have demonstrated their utility as 
markers of the vascular wall. For this study we have used the tomato 
Lectin (Lycopersycum esculentum agglutinin, LEA). 
This histochemistry was performed on 50 μm thick free-floating 
sections with FITC-conjugated Lectin lycopersycum (1:100; Sigma-
Aldrich; ref: L0401). The entire histochemistry is carried out in dark 
conditions, because the LEA primary antibody is attached to a green 
fluorescent molecule. 
• Firstly the sections were washed twice with PBS 0.1M. 
• The sections were placed in a blocking solution of PBS 0.1M+BSA 
5% (Sigma-Aldrich; ref: A7906) + Triton X-100 (Sigma-Aldrich ref: 
T-6878) 0.5% for 2 hours. 
• Add primary antibodies diluted in the blocking solution like 
previously stated and incubate overnight at 4º C. 
• Wash three times with PBS 0.1M. 
• Incubate 5 minutes with Hoechst 33258 (Sigma-Aldrich) 5μg/ml in 
PBS 0.1M. 
• Wash three times with PBS 0.1M. 
• Mount the sections in gelatinised slides and cover with 
Vectashield (Vector laboratories ref: x-0517) and cover-slides. 
Some representative cases were double stained with CD133. 
All fluorescence images were acquired with an Olympus Fluoview 
FV500 confocal microscope using sequential acquisition to avoid 
overlapping of fluorescent emission spectra. The images have been 
treated with FV 10-ASW 1.6 Viewer and Adobe Creative Suite 4. 
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4.8.-Immunohistochemistry 
Immunohistochemistry assay was carried out on paraffin sections 
against stem cell markers: Nestin (monoclonal anti-Nestin 1:200, Santa 
Cruz sc-33677), Osteopontin (monoclonal anti-Osteopontin 1:200, Santa 
Cruz sc-21742) and Ki-67 (monoclonal anti Ki-67 1:100; Monoclonal, 
DakoCytomation, M7248). 
• Deparaffinate the sections by two baths of 10 minutes in xylene. 
• Hydration by immersion in decreasing gradient alcohols every 5 
minutes in 100º, 96º, 80º, 70º, 50º and distilled water. 
• Immersion in methanol + H2O2 (Foret; ref: 7722-82-1) 4% during 20 
min. 
• Boil 5 minutes in citrate buffer (pH=6.0) and let it cool. 
• Block with PBS 0,1M + BSA 1% (Sigma-Aldrich; ref: A7906) for 2 
hours. 
• Add the primary antibody diluted in the blocking buffer and 
incubate overnight at 4ºC in a moist chamber. 
• Wash twice with PBS 0.1M. 
• Add biotinylated secondary antibody as prescribed in the Anti-
mouse Vectastain ABC kit (Vector Laboratories, ref: PK-6102) and 
incubate for 1 hour in a moist chamber. 
• Add avidin-biotin-peroxidase complex as prescribed in the Anti-
mouse Vectastain ABC kit and incubate for 30 minutes in a moist 
chamber. 
• Wash twice with PBS 0.1M. 
• Develop the reaction with 3.3-diamino-benzidine (DAB) (Ref.: 8001, 
Sigma-Aldrich, 0.25 mg/ml) and H2O2 solution (0.01%). 
• Counterstain with Harris Hematoxylin for 45 seconds. 
• Dehydration by immersion in increasing gradient alcohols every 5 
minutes in 50º, 70º, 80º, 96º, twice 100ºC and twice xylene 
(Panreac; ref: 211679.174) 
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• Protect with cover-slides using DPX resin (Fluka Chemie, Ref.: 
44581). 
Negative controls omitting primary antibodies were performed on each 
run. Visualisation was made with an optical microscope (Olympus SA ref: 
BH-2). 
 
4.8.1-BrdU immunofluorescence 
The tissue was stored in a 30% sucrose (Panreac Química ref: 131621) 
solution in PBS 0.1M until cut into thick sections of 50 um with a cryotome. 
The immunohistochemistry was carried as follows: 
• Wash the sections twice with PBS 0.1 M. 
• The sections were placed in a blocking solution of PBS 0.1M+BSA 
5% (Sigma-Aldrich; ref: A7906) + Triton X-100 (Sigma-Aldrich ref: 
T-6878) 0.5% for 2 hours. 
• Incubate in HCl 2N at 37ºC for DNA denaturalisation for 30 
minutes. 
• Wash with Tetraborate sodium decahydrate (Sigma-Aldrich; ref: 
B9876) 0,1M at pH 8.5 for 10 minutes. 
• Incubate overnight at 4ºC with primary antibody against BrdU 
1:100 (Santa-Cruz; ref: sc-51514) in blocking solution. 
• Wash three times with PBS 0.1M. 
• Add the secondary fluorescent antibody FITC-conjugated anti-
mouse IgG (Ref.: F-9137, Sigma-Aldrich, 1:400) diluted in the 
blocking solution and incubate for 1h at room temperature. 
• Wash three times with PBS 0.1M. 
• Incubate for 5 minutes with Hoechst 33258 (Sigma-Aldrich) 
5μg/ml in PBS 0.1M. 
• Wash three times with PBS 0.1M. 
• Mount the sections in gelatinised slides and protect with 
Vectashield (Vector laboratories ref: x-0517) and cover-slides. 
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The visualisation was made with a fluorescent microscope (Olympus 
Optical SA: ref BX-41). 
 
4.8.2-Double immunofluorescence 
Brain sections 50 μm thick were used to locate stem cell markers 
(Nestin 1:400 ref: sc-21247 Santa Cruz, CD133 1:100 ref: ab-16518 
Abcam, OPN 1:300 ref: sc-21742 Santa Cruz, Notch-1 1:200 ref: bs-1335R 
Bioss) and to identify the relation of stem cells with tumoural vasculature 
(LEA 1:100; Sigma-Aldrich; ref: L0401, Von-Willebrand factor 1:100 ref: ab-
7356 Millipore), BBB (GluT-1 1:200 ref: 07-1401 Millipore, EBA 1:200 ref: 
SMI 71 Sternberger) and other structures (GFAP 1:400 ref: sc-6170 Santa 
Cruz, MAP-2 1:200 ref: M4403 Sigma , VEGF 1:200 ref: sc-152Santa Cruz). 
The immunofluorescence technique was carried out in 24 well plates with 
the following mix of the primary antibodies as stated in Table 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Policlonal    Ab 
 
 
Monoclonal 
GFAP VEGF Glut-1 Notch-1 CD133 Von-Willebrand 
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Ab 
Nestin Done Done Done Done Done - 
EBA - - Done - - - 
MAP-2 Done Done - - - Done 
LEA - - - - Done - 
Osteopontin Done Done - Done - - 
 
The secondary antibodies cocktail was formed of FITC-conjugated 
anti-mouse IgG (Ref.: F-9137, 1:400, Sigma-Aldrich) and TRITC-
conjugated anti-rabbit IgG (Ref.: T-6778, 1:400, Sigma- Aldrich) (Fig. 11). 
From step 5 onwards, the experiment is carried out in dark conditions, 
because the secondary antibodies are attached to fluorochromes. 
• Firstly the sections were washed twice with PBS 0,1M. 
• The sections were placed in a blocking solution of PBS 0.1M+BSA 
5% (Sigma-Aldrich; ref: A7906) + Triton X-100 0.5% (Sigma-
Aldrich; ref:T-6878) for 2 hours. 
Table 3: Double immunofluorescences performed in the 50 μm thick 
criotome sections. 
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• Add the primary antibodies diluted in the blocking solution as 
previously described and incubate overnight at 4º C. 
• Wash three times with PBS 0.1M. 
• Add the secondary fluorescent antibodies diluted in the blocking 
solution and incubate for 1h at room temperature. 
• Wash three times with PBS 0.1M. 
• Incubate 5 minutes with Hoechst 33258 (Sigma-Aldrich) 5μg/ml in 
PBS 0.1M. 
• Wash three times with PBS 0.1M. 
• Mount the sections in gelatinised slides and cover with 
Vectashield (Vector laboratories ref:x-0517) and cover-slides. 
 
 
 
4.9-Quantitative studies 
4.9.1-Positivity index for Nestin, Osteopontin, Ki-67 and BrdU 
Ag Ag Ag 
 
 1º Ab 
 
  2º Ab 
+ Alexa 488 
 
 
 
  
 
 
  
 
 2º Ab 
+ Alexa 568 
Figure 11: Schematic representation of a double immunofluorescence with 
different primary antibodies attached to their specific antigens. Then 
specific secondary antibodies with fluorescent binding are added. The result 
can be viewed with a fluorescent microscope. 
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We calculated the positivity index for Ki-67, Nestin and Osteopontin in 
85 gliomas classified in three different degrees of malignancy according to 
previous work carried out in our laboratory (Bulnes et al., 2009), 31 of 
grade I, 24 of grade II and 30 cases of grade III. 
To calculate the positivity index of Nestin and Osteopontin , 400 
tumour cells were counted at high magnification (×400) with a reticule of 
62500 μm2, from the most representative area of the tumour, and the 
percentage of cells expressing the antigen was reported. We only counted 
the positive cells that were not in contact with the vessels and only when 
the cells were located individually, and not when they appeared as dense 
aggregations of cells. KI-67 index was quantified the same way, but 
counting the positive nuclei. 
Only the cells inside the quantification grid and the cells in contact 
with two external sides were counted (as shown in Fig. 12). 
 
 
 
 
 
 
 
 
 
 
 
4.9.2-Nestin expression vs. cell proliferation 
     
     
     
     
     
Figure 12: Scheme of the quantification grid and the cells that are counted. 
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We calculated the number of BrdU and Nestin-positive cells/mm2 in 21 
cases: 6 of grade I, 6 of grade II and 9 of grade III. To calculate this data we 
counted the number of BrdU positive cells in five different and 
representative areas of the tumour. Brain sections were visualised using a 
fluorescent microscope (Olympus BX41). Controls without primary 
antibody showed no staining. Then the means of BrdU and Nestin positive 
cells per mm2 were calculated. 
In order to avoid the inter-observer variability factor, the quantitative 
evaluation was performed by the same researcher. 
 
4.9.3-Quantification of Nestin spheroid aggregates 
We also counted the number and density of Nestin+ intratumoural 
aggregates in the same cases as the positivity index for Nestin, counting 
as an aggregate a group of six or more Nestin-positive cells. Finally, the 
area of the clusters, segregated into 8 from stage I; 67 from stage II and 
134 from stage III tumours, was calculated using Image J software, 
measuring the area with the freehand selection tool (Fig. 13). 
Quantifications were performed by the same researcher in order to 
avoid inter-observer variability. 
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4.10-Statistical analysis 
All the statistical analysis was performed using GraphPad Prism 5.00. 
For the behavioural analysis, ANOVA tests were performed when 3 
groups were available, and a t-test when there were only 2 groups to 
compare. 
For differences in the mean age of tumour apparition, a t-test was 
performed. 
An unpaired t-test was used to analyse differences among the 
averages of Nestin, its niches and Osteopontin positivity index. To 
compare Nestin and proliferation indexes, a r of Pearson was performed. 
Data is described as mean ± SEM. A p value less than 0.05 was 
considered statistically significant. 
 
 
Figure 13: Representation of Nestin+ aggregates quantification with Image 
J software. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
V.-Results 
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5.1-Clinical diagnosis 
This part of the study was performed in order to establish an early and 
non-invasive way to diagnose, or at least to suspect, CNS tumours, before 
the rats develop severe clinical symptoms (cachexia, abnormal posture or 
respiratory difficulties). 
 
5.1.1 Evaluation of general welfare status 
For this analysis we have separated the ENU-exposed rats into two 
groups according to the score obtained in the adapted tests from Morton & 
Griffith: rats with a welfare score=0 (without physical symptoms of 
disease) and rats with a welfare score >0 (with physical symptoms of 
disease). No parameter was altered in a way that drew attention. 
From the homecage system (Phecomp cage) and open-field tests we 
have obtained the data shown in Table 4. The weight was measured before 
the homecage stay and then food and water intake, % of time moving, 
number or rearings, total distance walked, and % of exploration were 
recorded. In this table, we have separated male and female rats and the 
mean and standard deviation for each parameter is shown. The data is 
shown for each time when the tests were carried out, in order to observe 
the temporal variation of the studied parameters. 
The results of the Table 4 show that female rats from  the 7th month 
onwards, and the male rats from 6th months onwards, only displayed a 
welfare score=0, because the animals with physical symptoms were 
sacrificed as has bee previously described. The data shows that there is a 
huge variability in the studied parameters among all the rats, and many 
times there is no pattern in the parameters along time. 
The majority of the behavioural differences were observed in the 
homecage stay test, rather that in the open-field test. We can observe that 
many parameters tend to decrease from the control group to the “score=0 
group” and even more to the “score>0 group”, but this does not always 
happens. On the other hand, in many of the cases there is more variability 
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in the numerical values of any parameter of the “score=0 group” and the 
“score>0 group” than in the control group. This can be explained because 
in these groups there are rats in different states of health, expanding the 
variability. 
A surprising fact is that in some cases, the rats in the “score=0 group” 
and the “score>0 group” weigh less than control rats, despite of having a 
bigger food intake and having made a greater amount of movement. 
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Age and 
condition 
Weight 
(g) 
Food 
(g) 
Drink 
(ml) 
Distance 
(m) 
Rearing 
(n) 
%  
interior 
%  
movement 
Distance 
(cm) open 
Rearing 
(n) open 
% 
interior 
open 
% 
movement 
open 
4 months 
control 
413.8±
9.465 
27.08± 
3.13 
18.15± 
2.3 
62.31± 
11.05 
1299± 
218.3 
18.41± 
2.42 
16.53±0.65 - - -  
4 months 
score=0  
352.0±
28.6 ** 
19.35± 
2.03 
18.45± 
1.95 
68.87± 
2.43 
1212± 
186 
18.39± 
2.84 
16.6±0.52 - - - - 
4 months 
score>0  
295.0± 
40.41 
***, # 
16.63± 
5.65 
14.62± 
4.90 
51.37± 
10.81 
*, # 
527± 
99.4 
14.1± 
4.67 
13.7±2.49 - - - - 
5 months 
control  
433.8± 
4.8 
13.10± 
7.865 
27.18± 
5.979 
75.79± 
5.63 
1732± 
700.9 
30.70± 
11.38 
17.99± 
1.05 
- - - - 
5 months 
score=0  
351.7± 
21.4*** 
19.67± 
8.54 
22.63± 
6.985 
79.83± 
20.57 
1181± 
682.7 
21.97± 
7.014 
18.16± 
3.46 
2439± 
398.8 
53.83± 
13.88 
3.62± 
1.66 
51.38± 
8.28 
5 months 
score>0  
 
286.7± 
40.4 
***, ## 
8.92± 
15.45 
11.18± 
18.76 
56.36± 
10.96 
863.7± 
378.0 
10.63± 
7.92 
* 
15.90± 
3.35 
1858± 
526.8 
40.33± 
4.91 
1.57± 
0.47 
68.27± 
2.97 
Homecage Open-field 
MALE 
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 Weight 
(g) 
Food (g) Drink (ml) Distance 
(m) 
Rearing 
(n) 
% interior % 
movement 
Distance 
(cm) open 
Rearing 
(n) open 
% 
interior 
open 
% 
movement 
open 
6 months 
control (n=4) 
453.8±
2.4 
24.38± 
3.96 
27.95± 
3.88 
81.93± 
44.41 
2470± 
1804 
27.48± 
7.814 
18.48±2.16
1 
- - - - 
6 months 
score=0  
365.0± 
21.1 * 
30.4± 
3.72 
22.53± 
2.26 
82.3± 
17.52 
2013± 
2030 
17.54± 
11.74 
18.28±7.26
7 
2052± 
1418 
35.40± 
22.35 
6.360± 
5.849 
61.46±13.
68 
7 months 
control 
445.0± 
21.8 
21.36± 
1.03 
26.55± 
2.23 
114.8± 
37.5 
2034± 
538.3 
8.6± 
3.39 
24.68±1.7 1321± 
72.1 
41.5± 
15.5 
2.17± 
1.01 
61.28±2.8 
7 months 
score=0 
335.0± 
25.0 * 
- 23.96± 
6.72 
74.12± 
43.5 ** 
2881± 
625.5 
17.65± 
3.05 
15.1±0.7 
** 
457± 
258 * 
10.09± 
2.6 * 
0.35± 
0.35 
30.35±10.
6 
* 
7.5 months 
control  
508.8± 
8.8 
18.58± 
4.19 
28.01± 
5.27 
67.67± 
5.92 
2415± 
559 
21.7± 
3.96 
16.03±1.39 639± 
268 
6.5± 
3.88 
10.75± 
0.6 
39.05±11.
1 
7.5 months 
score=0  
382.5± 
17.5 ** 
17.22± 
7.36 
13.18± 
7.62 
78.46± 
8.25 
1373± 
536 
18.7± 
5.8 
17.05±2.15 810± 
356 
0.5± 
0.5 
16.9± 
16.6 
42.4±13.1 
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FEMALE 
 Weight 
(g) 
Food 
(g) 
Drink 
(ml) 
Distance 
(m) 
Rearing 
(n) 
% 
interior 
% movement Distance 
(cm) open 
Rearing 
(n) open 
% interior 
open 
% movement 
open 
4 months 
control  
268.8±
22.13 
18.64± 
3.94 
20.76± 
1.81 
84.87± 
8.6 
1020± 
88 
20.18± 
0.92 
28.97± 
3.28 
- - -  
4 months 
score=0  
 
209.1±
22.44 
*** 
16.69± 
1.32 
19.21± 
1.64 
90.65± 
3.95 
 
1054± 
67 
21.12± 
2.58 
25.99± 
6.55 
*** 
- - - - 
4 months 
score>0 
 
164.5±
22.57 
***, 
### 
3.29± 
1.7 
***, 
### 
4.28± 
2.54 
***, 
### 
45.34± 
2.68 
***, ### 
418± 
163 
***, ### 
18.25± 
5.81 
12.16± 
0.68 
***, ### 
- - - - 
5 months 
control  
300.0± 
35.82 
16.55±
4.83 
22.51± 
10.47 
89.06± 
16.27 
1090± 
541.8 
29.43± 
25.37 
21.19± 
2.58 
4110± 
1050 
42.00± 
9.764 
11.63± 
4.884 
73.93± 
31.96 
5 months 
score=0  
249.4±
24.04 * 
23.44±
5.23 
30.24± 
14.82 
104.9± 
34.06 
947.2± 
353.7 
21.80± 
11.79 
21.20± 
5.02 
3215± 
1092 
41.44± 
14.38 
6.54± 
4.03 
71.30± 
12.23 
5 months 
score>0 
 
 
193.3±
36.70 
***, ## 
19.05±
10,60 
15.04± 
8.99 
76.60± 
29.26 
709.3± 
540.0 
21.52± 
16.60 
20.83± 
7.03 
3002± 
751.7 
49.33± 
19.06 
6.85± 
4.99 
56.43± 
18.08 
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 Weight 
(g) 
Food 
(g) 
Drink 
(ml) 
Distance 
(m) 
Rearing 
(n) 
% 
interior 
% movement Distance 
(cm) open 
Rearing 
(n) open 
% interior 
open 
% movement 
open 
6 months 
control  
328.8±
25.94 
20.80± 
10.73 
31.33± 
9.034 
94.45± 
14.32 
1026± 
363.2 
18.18± 
4.882 
19.84±1.73 
 
- - - - 
6 months 
score=0  
263.3±
25.17 
14.53± 
2.102 
16.49± 
16.03 
87.18± 
42.29 
749.3± 
444.5 
16.80± 
14.88 
16.35±6.27 
 
3366± 
1661 
40.00± 
13.11 
7.93± 
4.15 
79.07±13.4 
6 months 
score>0 
 
213.8±
48.61 
** 
10.31± 
10.30 
8.405±
10.34 
* 
67.02± 
34.64 
430.0± 
444.1 
18.33± 
14.70 
16.50±7.69 
 
1797± 
1080 
22.13± 
21.48 
5.66± 
4.79 
49.06±6.8 
# 
7 months 
control  
317.5± 
18.87 
14.37± 
5.52 
22.24±
6.05 
109.3± 
1.2 
761.3± 
79.67 
15.05± 
3.47 
24.68±1.8 4106± 
230 
22.50± 
1.31 
9.87± 
1.56 
66.25±9.13 
7 months 
score=0  
275.0± 
15 
17.69± 
0.01 
34.31±
15.26 
70.54±5.2 
** 
798.5± 
177.5 
26.5± 
18 
15.1±0.7 
** 
2293± 
155 ** 
22.35± 
9.50 
3.15± 
2.05 
45.45±26.05 
7.5 months 
control  
333.8± 
12.8 
16.82± 
5.89 
19.74± 
5.29 
1224± 
11.7 
1837± 
398 
30.5± 
3.6 
23±2.1 
 
4486± 
349 
30.01± 
5.20 
13.15± 
3.33 
79.93±2.9 
7.5 months 
score=0  
270.0± 
20 * 
14.29± 
2.81 
25.93± 
0.31 
597.8± 
57.1 ** 
950.5± 
293 
10.35± 
2.64 * 
13.46± 
0.8  ** 
2339± 
633 * 
10.03± 
2.10 
2.45± 
0.35 
46.1±12.1  
* 
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 Weight 
(g) 
Food 
(g) 
Drink 
(ml) 
Distance 
(m) 
Rearing 
(n) 
% 
interior 
% movement Distance 
(cm) 
Rearing 
(n) 
% interior % movement 
8 months 
control (n=4) 
342.5± 
10.31 
20.19± 
9.19 
31.6± 
5.38 
67.21± 
3.27 
673.5± 
91.5 
12.3± 
4.47 
15.8±1.17 - - -  
8 months 
score=0 
 
307.5± 
57.5 
18.05± 
2.01 
20.94± 
4.9 
153.0± 
77.4 
843.8± 
101.23 
63.25± 
10.85 ** 
27.33±10.33 - - - - 
 
 
 
 
 
 
 
 
Table 4: Mean of the measured parameters after the homecage stay and open-field test. Standard deviation is represented. 
Grey boxes represent significant statistical differences; * means significant statistical difference rewarding control group, and # 
means significant statistical difference rewarding score=0 group. 
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As we can see in Table 4, it is not possible to determine the status of the 
animals only with the welfare score of the modified Morton & Griffith table 
(because there are behavioural alterations in both the “welfare score=0” and 
the “welfare score>0” groups). Nevertheless, the Morton & Griffith test helped 
us to further define the groups to study behavioural alterations. 
The variable that most changed in any group with respect to controls was 
the weight. Nevertheless, this alone does not provide enough information 
about the health status, and therefore we analysed the behavioural 
parameters individually. 
 
5.1.2 Individual behavioural analysis 
For this study, the same parameters as the ones used before were 
compared to the mean value of the control group for their age (shown in Table 
5). Individual values of each test were considered abnormal when they were 
outside the 95% Confidence Interval (CI) of the mean, which implies there is a 
statistically significant difference compared with the control group. 
We have not taken into account the weight of the rats, since we have seen 
that there is a decrease of the mean weight in the rats at all ages in 
comparison to control rats (70% of the time it was a significantlly statistical 
difference (p<0.05). Only in one of the 74 performed tests did the open-field 
test provide more information than the homecage stay. In all other cases, the 
open-field test did not provide extra information over the homecage. 
Only one rat did not develop any tumour, so the total number of tests 
passed by ENU-exposed rats that developed at least one tumour was 74. 
From these 74 tests, Table 5 shows the relationship between the welfare 
score and the alterations in the behavioural parameters of the total tests 
performed. 
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Score=0  
(n=53) 
Score>0 
(n=21) 
 
No alterations vs 
control mean 
(n=31) 
0.392 
(n=29) 
A 
0.027 (n=2) 0.419 
Increase in any 
value vs control 
mean (n=19) 
0.257(n=19) 
B 
0.0 (n=0) 0.257 
Decrease in any 
value vs control 
mean (n=24) 
0.054 (n=5) 
0.270 (n=19) 
C 
0.316 
 0.724 0.276 1 
 
The results in Table 5 show that from 21 animals that started the test 
with a score >0, only two cases showed an increase in any of the variables 
studied (6.5% of the time). In all other cases (93.5%) the rats displayed a 
decrease in at least one of the variables. Not having variations in any variable 
correlated positively (in 93.55% of the cases) with a healthy state of the rat 
(indicated by a score=0). An increase in the behavioural parameters correlated 
at 100% with a welfare score=0. 
This table also shows 3 big groups of rats with a specific welfare score 
and behavioural tests correlation. Rats in Group A show a welfare score of 0 
with no alterations in the homecage or open-field tests (these would be 
Table 5: Contingency table representing the different groups of rats and 
their welfare score. N means the total tests performed in each category. 
Group A (green) are rats in good health status, Group B (orange) are rats 
without physical symptoms but an increase in any of the measured 
parameters and Group C (red) show physical symptoms observable with the 
Morton&Griffith test and a decrease in at least one parameter. 
Morton & Griffith welfare score 
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healthy rats); Rats in Group B , that are rats in a state of alarm, prior to 
showing physical problems in the welfare test; and finally, there is Group C, 
that are rats with physical symptoms of the tumours. The mean time that rats 
took to go from Group A to B is of 34.8 days, and from Group B to Group C of 
29.8 days. We also calculated the mean elapsed time for the rats that went 
directly from Group A to Group C finding that this was 29.6 days (very similar 
to the time for going from Group B to Group C). 
From 24 rats that started with a score=0 and had any alteration in the 
behavioural variables with respect to controls, 19 of them showed an increase 
in one or more of the variables, compared with control rats (82.6%). Only in the 
remaining 4 cases did we observe a decrease in variables, after a score=0 in 
the welfare table. Two of these cases were from the same rat that developed 
an extra-CNS tumour (breast tumour). In the other two instances, the rats 
developed a glioma. 
Observing the chronology of behavioural evaluation (followed by the rat’s 
death) in Table 6, it can be observed that of all the rats that were sacrificed 
after the first evaluation (4th month of age), 61.5% of cases belong to Group C, 
which means that 8 rats made their debut in the most severe group. The rest 
of the animals at this timepoint belonged to Group A. These lasts were 
sacrificed without having behavioural alterations. In total, 42% of rats from 
Group C only passed the first behavioural test. Remaining cases sacrificed 
after the 2nd and 3rd evaluations, came from asymptomatic groups (5 cases 
from Group A and 6 from Group B). 
After the second evaluation, only half of the sacrificed rats belonged to 
Group C (5 rats came from Group A and one from Group B). Nevertheless, 
there were also a 25% of rats that were sacrificed belonging to Group A and 
the other 25% belonging to the group with no behavioural parameter altered 
and “welfare score>0” or decrease in behavioural parameters and “welfare 
score=0” 
In the third evaluation, it is possible to observe the expected tendency in 
these rats; they started belonging to Group A in the first evaluation, evolved to 
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Group B in the second one and lastly ended into Group C just before being 
sacrificed. 
Rats that survived more than 7 months do not show any pattern in their 
behavioural parameters over time. 
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Group A (no parameter altered and 
“welfare score=0”) 
Group B (increase in behaviour and 
“welfare score=0”) 
Group C (decrease in behaviour 
and “welfare score>0”) 
No parameter altered and “welfare 
score>0” 
Decrease in behaviour and 
“welfare score=0” 
4th month 5th month 6th month 7th month 7.5 month 8th month 
Table 6: Chronology of the behavioural evaluations and the end point of the studied animals. 
5 15 20 25 3010 5 15 20 25 30105 15 20 25 3010 5 15 20 25 3010 5 10 15 5 10 15
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Finally, we observed that the most repeatedly altered parameter vs. 
control rats in Groups B and C was the distance run as seen in the Table 7. 
Rats in Group B mainly had differences in parameters related with the mobility 
(distance and rearings), while rats in Group C had differences vs. control 
group regarding intake parameters (water and food intake). 
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 4 months 5 months 6 months 7 months 7,5 months 8 months 
Group B 
Rearing (n=4) Distance (n=4) Distance (n=2) 
% moving (n=2) 
Distance 
 (n=4) 
Distance (n=3) 
% interior (n=3) 
Distance 
% moving 
% interior 
Group C 
↓ Food (n=7) 
↓ Drink (n=7) 
↓ Distance (n=7) 
↓ Distance (n=4) 
↓ Drink (n=4) 
   
Table 7: The most repeated parameters that were altered in ENU-exposed rats vs control rats. Parameters in Group B were 
increased vs control and in Group C are decreased. 
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5.1.3-Survival time depending on behavioural status 
The survival time after the last behavioural tests shows that rats that 
belong to Group A, and were sacrificed in this status (n=9) lived a further of 
23.8±3.1 days (median= 26; range=3-31) after the tests. Rats from Group B 
rats that were sacrificed in this status (n=3) have a slightly shorter survival 
time, with 16.03±7.0 days (median=9; range=9-30) and Group C rats (n=19) 
that were sacrificed in this status have only 14.11±2.15 days (median=11; 
range=3-31) of mean survival time. There is a statisticallly significant 
difference between the Groups A and C (*p<0.05). The mean survival time is 
slightly higher in the rats in Group A, than in those in Group B, but there is no 
statistically significant difference (Fig. 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Mean survival time of the rats after the behavioural tests. The 
rats with a score higher than 0 in the welfare test and a decrease in any 
variable in the test were the rats with lower survival time. There is a 
statistically significant difference between Group A and Group C. 
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5.2-Tumour analysis 
For this part of the study we used several techniques in order to correctly 
classify the tumours induced after the ENU-prenatal administration. These 
tumours were classified into: intracranial intraaxial tumours, intracranial 
extraaxial tumours, spinal cord tumours and extra-CNS tumours. 
 
5.2.1-ENU-induced tumour incidence 
From the 94 sacrificed rats, at least one tumour was identified in 88 of 
them, so the incidence of tumour development was 93.61%. Our results show 
30 extraaxial tumours that in some cases grew together with the intraaxial 
tumours. The total number of tumours developed is shown in Table 8. Besides 
62 rats with at least one intracranial tumour (some rats displayed more than 
one at the same time), there were also 4 spinal tumours (composed of liquid 
protuberances) in the last third of the medulla, associated with the nerves of 
the sacro-lumbar zone. Finally, two breast masses were detected and only 6 
rats had not developed any tumour at sacrifice time. 
 
CNS tumours % Incidence (n=94) 
Total tumours 93.62 
Intracranial intraaxial 65.96 
Intracranial extraaxial 31.91 
Spinal cord tumours 4.25 
 
5.2.2-Intracranial tumour diagnosis 
The intracranial tumours are divided into intraaxial tumours (which are 
gliomas of different malignancy; including multifocal gliomas) and extraaxial 
tumours. Extraaxial tumours after prenatal exposure to ENU have been 
previously reported to be schwannomas and meningiomas (Zook and 
Table 8: Incidence (number of rats that show at least one tumour) of the 
different tumours induced after the prenatal exposure to ENU. 
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Simmens, 2000), but are not the primary object of this study. In total, gliomas 
including a multifocal location were found in 35% of the rats, who developed 
91 gliomas overall. 
 
5.2.2.1-Intraaxial tumours 
The MRI study of 13 rats at the 5th and 6th month of age showed that rats 
did show intracranial tumours as soon as this age. In total we could observe 
20 tumours; 12 of them were intraaxial tumours and 8 were extraaxial. In the 
MRI, T1 and T2 images showed hyperintense signals for mid and advanced 
intraaxial tumours (later identified as gliomas), whereas small sized, less 
malignant tumours only showed hyperintense signals in T2 (Fig. 12), without 
gadolinium capture in T1. Advanced-stage tumours show heterogeneous T1 
signalling and a more homogeneous hyperintense signalling of T2. The 
intraaxial tumours showed histopathological features similar to human 
gliomas e.g.: diffuse infiltrating border, necrotic areas, haemorrhages, cysts, 
cellular anaplasia, nuclear atypias, high mitosis and vascular proliferations 
among others. There is a predominance of oligodendroglial-like tumours. 
According to these characteristics and the previous work carried out in 
our laboratory (Bulnes-Sesma et al., 2006), we have classified the intracranial 
intraaxial gliomas in three different stages: 
 
Stage I gliomas correspond to cell proliferations with small to middle size 
cells proliferations forming well-delimited tumours, mainly associated with 
subcortical white matter (Fig. 15 j). They are made up of isomorphic round 
cells, with well-defined regular nuclei (Fig. 15 m), a clear halo around them 
and fine microvessels constituting a network mimicking normal brain 
microvasculature. 
Stage II gliomas are mainly constituted by anaplastic tumours of small, 
round cells typical of oligodendrogliomas. Macroscopically, these tumours 
appear as a soft mass of tissue with small foci of haemorrhages (Fig. 15 k). 
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These tumours show sporadic cellular aberrations such as nuclear 
polymorphism (Fig. 15 n). 
The advanced and most malignant stage III is equivalent to anaplastic 
oligodendroglioma or glioblastoma multiforme. Macroscopically, they usually 
have a lot of red zones of haemorrhages and they also usually have big cysts 
and brown/yellow necrotic areas (Fig. 15 l). These tumours are characterised 
by having many cellular aberrations such as nuclear and cellular 
polymorphism, atypical mitosis, and other features like necrosis and 
haemorrhages (Fig. 15 o). In this stage we can also find many vascular 
abnormalities like glomeruloid vessels and vascular proliferations.  
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f 
Figure 15: ENU-gliomas identification via MRI and H/E staining. T1 images 
of gliomas with hyperintese signal in stage II and III gliomas (a-c), T2 
images of the same gliomas with hyperintense signal in all stages gliomas 
(d-f), macroscopic view of gliomas after the rats perfusion (g-i), H/E 
staining of gliomas of different stage at lower magnification (j-l), H/E 
staining of the tumours at higher magnification (m-o). Scale bar (j-l)= 2.5 
mm, scale bar (m-o)= 25 μm. 
Stage I Stage II Stage III 
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In total, 91 gliomas had developed by the age of sacrifice in the rats prenatally 
exposed to ENU. The classification according to their malignant 
characteristics showed 31 stage I gliomas, 33 stage II gliomas and 27 stage 
III gliomas, as shown in Table 9. 
ENU-glioma stage % (N=91) 
Stage I 34.07 
Stage II 36.26 
Stage III 29.67 
 
5.2.2.2-Extraaxial tumours 
We could also observe in the MRI images, and macroscopically after the 
sacrifice of the rats, other intracranial ENU-induced tumours, which we have 
denominated extraaxial tumours (Fig. 16). These tumours were usually 
situated under the brain and were associated with the 5th cranial nerve. 
Sometimes the tumours also spread over the brain, as though they were 
wrapping it. When extraaxial tumours keep growing, they press against the 
brain, causing it to deform. Macroscopically, they are white and do not 
infiltrate the brain. In the MRI images, extraaxial tumours are more easily 
observed as a heterogeneous hyperintense signal in the T1 images with 
gadolinium capture (Fig. 16 a-c). 
Histopathologically, we have described the extraaxial tumours as high 
cellular-density tumours (Fig. 16 g, h), with haemorrhagic process and 
hemosiderin deposits, as we can see in Figure 16 i. Extraaxial tumours did not 
usually show necrotic areas; only the most malignant ones have necrosis. 
According to previous research and to work carried out in our laboratory, they 
are malignant peripheral nerve stealth tumours (MPNST) (Bulnes-Sesma et 
al., 2006) positive for S-100 and negative for GFAP and NF, and meningiomas 
(Zook et al., 2000). 
Table 9: Percentage of gliomas developed in each stage of development. N 
means the total number of gliomas 
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5.2.3-Mean rat survival time and tumour classification 
According to the age of death of the rats and the consequent tumoural 
identification, we calculated the mean survival time of the different 
intracranial tumours. When one or more tumours appeared, we took into 
consideration the tumour with the highest degree of malignancy, grading 
them from highest to lowest degree of malignancy: stage III glioma, extraaxial 
tumours, stage II glioma and stage I glioma. The age of sacrifice of all the rats 
ranged from 113 to 276 days of age (Fig. 17). 
Looking at the data, extraaxial tumours and stage I gliomas are the CNS 
tumours with the shortest survival times, with a mean age of 178 days of age, 
Figure 16: Extraaxial tumours identification via MRI and HE/staining. a-c: T1 
MRI images of extraaxial tumours. d-f: microscopical view of the extraaxial 
tumours. g, h: H/E staining of the extraaxial tumours showing their 
characteristical hemorrages and cellular density. Scale bar= 2.5 mm. 
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while stage III gliomas are the ones with the longest survival times, with a 
mean age of 215 days. 
 
Tumour Mean survival time (days) 
Stage I gliomas 178.5±20.43 
Stage II gliomas 195.6±7.81 
Stage III gliomas 215.3±5.91 
Extraaxials 178.6±9.41 
 
5.2.4-Correlation of clinical diagnosis with the classification of ENU tumours 
After the histopathological classification of the ENU-tumours, we tried to 
see if there is a clear correlation between the altered parameters and the 
diagnosed tumours. As we can see in Table 10, only in the case of rats with 
gliomas there is a parameter (distance) that was altered when the rats did not 
showed clinical symptoms (and they had a welfare score=0). As previously 
mentioned, we did not take the weight into account, because it is altered at 
almost all ages after exposure to ENU. 
Figure 17: Mean survival time of apparition of the CNS tumours induced by 
ENU prenatal exposure. 
There is a significant difference in the mean age of intraaxial vs extraaxial 
tumours, *p<0.05 (a). Mean age of all the intraaxial tumours (divided in 
stage, I, II, III tumours), and it can be observed a statistical significant 
increase in the mean time of apparition between stage I and III, *p<0.05 (b). 
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5.3-Stemness markers expression and distribution 
Nestin is the leading stem cell immunomarker used in this study. This 
antibody is expressed in all stages of ENU-glioma, and its expression 
increases significantly as tumoural malignancy increases. In the gliomas, 
Nestin expression can be found in cells that show different morphologies and 
tumour distribution in the different stages. 
 
5.3.1-Nestin expression in the different stages 
After the quantification of psotovity index of Nestin (mean number of 
Nestin+ cells) in the three stages of the gliomas, we have clearly observed an 
increase in Nestin expression within the glioma progression. In the initial 
stage the positivity index for Nestin is 5.26 ± 0.60 (n=30), in the intermediate 
stage is 10.25 ± 0.91 (n=25) and 15.94 ± 1.27 in the most advanced stage 
(n=31) (Fig. 18). 
 
 
 
 
 
 
 Most altered variable 
Glioma   Distance (60%) 
Extraaxial None 
Spinal cord None 
Extra CNS ↓ Distance and ↓ in all open-field variables 
Table 10: Most times altered variables in rats with the different classified 
tumours developed in the rats with welfare score=0, excluding the weight. 
60% of the rats that were identified with a glioma, had previously an 
increase in the distance run during the homecage stay prior to symptoms. 
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BrdU and Ki-67 indexes were both quantified to assess the degree of 
malignancy of ENU-gliomas. After quantifying the index of BrdU expression 
(Fig. 19 a), we found that its expression is increased during tumour 
development with astatistically significant difference between stage I 
(81.6±3.6 n=6) and stage II (147.1±12.1 n=6) with p<0.0001 (***) and stage I 
and stage III (171.6±14.66 n=9) with p<0.0001 (***). Nestin quantification in 
the same cases (Fig. 19 b) showed a statistically significant difference 
between all stages. Stage I (80.82 ± 5.216 n=6) and stage II (118.7 ± 5.261; 
n=6); p<0.001 (***), stage I and stage III (144.7 ± 3.342; n=9); p<0.001 (***) and 
stage II and stage III; p<0.01 (**). 
Ki-67 expression has been previously evaluated in 26 cases, which were 
also quantified for Nestin in Fig. 18. The expression of this antibody also 
increases with the tumoural development and is significantly different 
between all groups (Fig. 19 c). 
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Figure 18: Index of Nestin positivity in all stages. There are significant 
statistical differences between stage I vs stage II (***p<0.001), between 
stage I vs stage III (***p<0.001) and between stage II vs stage III 
(**p<0.01). 
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After performing a correlation test, the results show a statistical 
significance using the “r of Pearson” coefficient in Nestin vs. BrdU (*** 
p<0.001) and Nestin vs. Ki-67 (*** p<0.001). These data suggest a positive 
correlation between the expression of BrdU, Ki-67 and Nestin markers. 
Unfortunately, double staining of Nestin and BrdU could not be performed. 
 
5.3.2-Distribution of stemness markers in the different stages 
Nestin-positive cells can be found from stage I of ENU-gliomas as cells 
with a big cytoplasm and large prolongations, and are found scattered 
throughout the tumoural mass (Fig. 20 c) and in a few cases we have 
observed Nestin+ cells forming groups of small round cells with scarce 
cytoplasm and hyperchromatic nuclei that we have called “spheroid 
aggregates” (Fig. 20 f). At the second stage of glioma development, Nestin is 
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Figure 19: Proliferation markers quantification. a) BrdU positive cells/mm2 
BrdU expression increases significantly as the gliomas grow, b) Nestin 
positive cells/mm2 in the same tumours also get increased. c) Ki-67 
positivity index. Increases as well significantly.(**p<0.01, ***p<0.001) 
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expressed in two different patterns; around slightly tortuous vessels as 
perivascular expression or as “spheroid aggregates”. The expression of 
Nestin in the most malignant stage depends on its location; in the interior of 
the tumour there are many of these aggregates of very different sizes (with a 
tendency to be increasingly big as the number of these arrangements 
increases). Adjacent to the aberrant vessels, such as the dilated and 
glomeruloid-like vessels appear numerous isolated Nestin-positive cells 
forming the perivascular expression, and in addition there is a border 
expression with large elongated cells showing positivity for Nestin distributed 
heterogeneously. It is also very frequent the find Nestin-positive cells inside 
the pseudopalisades surrounding the necrotic areas of advanced stage 
gliomas (Fig. 20 i). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: H/E staining and Nestin immunohistochemistry during glioma 
development. a, b: In the first stage of ENU-gliomas there are few Nestin-
positive cells, distributed randomly inside the tumour (c). In the intermediate 
stage (d, e) some expression in spheroid aggregates begins to appear (f). In 
the most advanced stage (g, h) there is Nestin expression around the 
necrosis forming pseudo palisades. (i).Scale bar (a, b, d, e, g, h) =2.5 mm; 
scale bar (c, f, i) =10 μm. 
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Nestin expression is located directly adjacent to the vessels, around the 
wall of the aberrant vessels. Nestin-positive cells are found around all types 
of vessel and display large cellular prolongations. Nestin perivascular 
expression can be observed around the tortuous vessels (Fig. 21 a, b), as well 
as around dilated vessels (Fig. 21 c), frequently in patches, and is greates 
around the glomeruloid-like vessels (Fig. 21 d). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Spheroid aggregates are characterised as being groups of at least six 
cells positive for Nestin. Cells in these aggregates have a characteristic 
morphology, with a small, round small cytoplasm and few or no cytoplasmatic 
prolongations. The aggregates appear in all the stages of glioma development 
and tend to form a circular shape (Fig. 22), differing greatly in their size; some 
of them consist of just six cells (Fig. 22 a, c) while others are clearly bigger, 
with a great number of cells (Fig. 22 b, d). The huge aggregates tend to 
a b 
c d 
Figure 21: Nestin immunohistochemistry around tumoural vasculature. 
Nestin is expressed close to the endothelium in the slightly aberrant vessels 
(a, b), around huge dilated vessels (c), and around the most aberrant 
vessels; glomeruloids (d).Scale bar (a) =10 μm; scale bar (b, c, d) =25 μm. 
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maintain the shape and mostly, the cells inside maintain their morphology. 
However, sometimes we observed cells with cellular prolongations and some 
vessels (mostly, but not exclusively) in the border or inside the aggregates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In addition to Nestin expression, some ENU-glioma cells express other 
stem cells markers like CD133, Osteopontin and Notch-1. 
CD133 expression in the tumour can only be observed in stages II and III 
around aberrant tumoural vessels as perivascular expression (Fig. 23) or  
a b 
c d 
Figure 22: Different “spheroid aggregates” that we observed with Nestin. 
Immunohistochemistry (a, b) and immunofluorescence (c, d). a) and c) show 
Nestin aggregates composed of few cells. b) and d) show bigger spheroid 
aggregates, with occasional fibbers of Nestin, besides the small round cells. 
Scale bar =75 μm. 
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forming part of “spheroid aggregates” (Fig. 23 c), similar to Nestin 
expression. 
 
 
 
 
 
 
 
Osteopontin expression begins in the first stage (Fig. 24 a) as isolated 
cells inside the tumoural mass, but is in stages II (Fig. 24 b) and III (Fig. 24 c) 
that the OPN-positive cells appear distributed mostly around the tumoural 
border. 
 
Figure 23: Immnunofluorescence against CD133 in the different stages of 
glioma development. Stage I gliomas (a) do not show CD133 positivity, 
CD133+ cells can only be seen in stages II (b) and III (c) of glioma 
development (b, c). CD133+ cells are located around the abnormal 
vasculature or forming spheroid aggregates inside the tumoural mass (c). 
Scale bar=1 mm. 
 
a b c 
Figure 24: Immunohistochemistry against OPN in the different stages of 
glioma development. OPN cells can be seen since the early glioma stages., 
but it is only during the most malignant stages (b, c) that its expression gets 
organized in the tumoural border. Scale bar =1 mm. 
a b c 
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OPN quantification showed an increase in its expression as tumoural 
malignancy increases. In the initial stage, positivity index for OPN is 4.11 ± 
1.52 (n=6), in the intermediate stage is 8.60 ± 1.14 (n=14) and 11.43 ± 1.03 in 
the most advanced stage (n=8). We have appreciated a statistical increase in 
OPN expression between stage I and stage II p<0.05 and stage I vs. stage III 
p<0.01 (Fig. 25). 
 
 
 
 
 
 
 
 
 
Notch-1 expression could only be observed as fibrilar cells in the border 
and peritumoural area in stages II and III (Fig. 26 b), and sometimes in the 
interior in lesser amounst and without any pattern (Fig. 26 c). There is an 
increase in the area covered by Notch-1 expression as the gliomas become 
malignant, but we have not quantified it. 
 
 
 
Figure 25: OPN quantification in the different glioma stages showing an 
increase in its expression. There are statistical significant differences 
between stage I vs stage II (*p<0.05) and stage I vs stage III (**p<0.01). 
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Following the results of the location of Nestin and other stem cell markers, 
it was found that the expression of Nestin and other markers depends on the 
degree of malignancy of the glioma and their location inside the tumour as 
follows: 
As regards the hypoxic interior area of mild to advanced gliomas, Nestin-
and CD133-positive cells appear mainly as intratumoural aggregates of cells 
taking spheroidal shapes. There is also expression of Nestin and CD133 
around tortuous and hyper-dilated vessels. In the tumoural border, the 
majority of the Nestin+ cells appear around the glomeruloid vessels. There is 
positivity for CD133 around these types of vessels. In the border isolated cells 
positive for Nestin are also shown. There are also isolated OPN-positive cells 
and Notch-1 expression in this zone. Both OPN and Notch-1 are very slightly 
expressed in the interior of the tumour. 
 
5.3.3-Perivascular expression of markers related to stem cells 
The ENU-induced tumours show a high vascular density with many 
vascular aberrations. These aberrations are all the typical vascular features 
that are also present in human gliomas; like tortuous vessels, vascular wall 
proliferations and vascular glomeruloids. 
 
Figure 26: Immunofluorescence against Notch-1 in the different stages of 
glioma development. In stage I gliomas (a) there is no Notch-1 positivity, 
but in the border of the malignant stages (b) it is expressed, as well as in 
some areas of the tumour interior (c). Scale bar =1 mm. 
a b c 
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In the ENU-gliomas we have observed three categories of vascular 
aberrations; those are, in order of malignancy: tortuous vessels, present since 
the first stage of glioma development (Fig. 27 b); huge dilated vessels present 
since stage II of glioma development (Fig. 27 c) and glomeruloid-like vessels 
(Fig. 27 d), present only in the most malignant stage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a b 
c d 
Figure 27: Morphology of the vessels marked with LEA during glioma 
development. a) There can be observed normal vessels, b) tortuous vessels 
that appear when the tumour is not very malignant. In the most malignant 
gliomas there can be seen c) hyper-dilated vessels as well as glomeruloids d), 
these lasts mainly in the border of the tumours. 
Scale bar =50 μm. 
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The analysis of the BBB markers showed that both EBA (a protein 
expressed specifically by endothelial cells of rat brain barrier vessels) and 
GluT-1 are expressed on all types of aberrant vessels, but differently on each 
one. In the tortuous vessels, both markers are expressed in the endothelial 
cells and co-localizing (Fig. 28 a, d). Both markers also appear both co-
localizing on hyperdilated vessels, but sometimes in patches. In glomeruloid-
like vessels, GluT-1 expression remains, but EBA is sometimes totally 
unexpressed (Fig. 28 b, e). VEGF is expressed around all types of tumoural 
vessels, but slightly more intensely around dilated and glomeruloid vessels, 
and always more externally than the BBB marker EBA (Fig. 28 c, f). 
 
 
 
Figure 28: Immunofluorescence of BBB markers and GFAP in tumoural 
vasculature (a-c) EBA (green) and Glut-1 (red) and (d-f) EBA (green) with 
VEGF (red) in different types of vessels. Glut-1 can be seen around all types 
of vessels (a-c), while EBA expression gets lost in dilated (b) and 
glomeruoild-like vessels (c). VEGF is overexpressed around all types of 
vessels (d-f) Scale bar =75 μm. 
a b c 
d e f 
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Cells positive for Nestin are to be found around several abnormal types 
of vessels, such as the glomeruloid ones located directly adjacent to the 
vessel wall co-expressing slightly CD133. Cells positive for CD133 are located 
slightly externally from the Nestin+ ones around huge dilated vessels. CD133 
is only slightly expressed around tortuous vessels (Fig.29 a, f, k). 
CD133 is expressed externally in small and round cells outside and very 
close to the vascular endothelium marked with LEA in the hyperdilated 
vessels (Fig. 29 b, g, l) and both markers co-locate just slightly around the 
most aberrant glomeruloid vessels (Fig. 29 o). 
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Figure 29: Colocation (yellow) of stem cell markers (Nestin and CD133) and other specific markers (VEGF, LEA, GFAP and 
Glut-1) in the perivascular subpopulation. All tumours are counterstained with Hoechst (blue). a-c) Perivascular aggregates of 
Nestin+ cells are displayed adjacent to the gluT-1 positive cells. All of these vessels maintain the glucose transport of the 
BBB, patched sometimes around glomeruloid vessels. There is co-expression of Nestin-CD133 only around the glomeruloid 
vessels (i). CD133 is expressed externally from LEA (c, h, m), with both markers co-expressing only slightly around 
glomeruloid vessels. There are more Nestin+ cells than GFAP+ (d, i, n) and VEGF+ (e, j, o) cells in the perivascular aggregate. 
Some of the Nestin+ cells co-express VEGF and GFAP (i, j). Scale bar =50 μm. 
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Perivascular Nestin+ cells have a slight co-expression with GFAP (Fig. 29 
c, h, m) and VEGF (Fig. 29 d, i, n), around dilated and glomeruloid vessels. The 
few cells that co-express Nestin-GFAP and Nestin-VEGF (Fig. 29 h, I, m, n 
arrows) are not located directly at the vessels wall, because VEGF and GFAP 
are expressed more externally with respect to the vascular wall than Nestin, 
especially around the hyperdilated vessels. Nestin expression is located 
directly close to the BBB marker Glut-1 around the tortuous and glomeruloid 
vessels (Fig. 29 e, j), but when vessels become dilated (Fig. 29 o) Nestin 
expression moves away from the endothelial wall 
Taking a closer look at the glomeruloid like vessels, we could clearly 
observe how Nestin is expressed (Fig. 30 a) internally compared to Glut-1. 
Nestin+ cells co-express with VEGF (Fig. 30 b) at some points of the 
glomeruloid vessels. CD133 expression co-localises with LEA expression (Fig. 
30 c), even though there are more CD133+ cells surrounding these vessels 
than directly close to the endothelial wall. 
 
 
 
Figure 30: Double immunofluorescence of the glomeruloid vessels. a) 
Expression of Nestin (green) and Glut-1 (red) around glomeruloid-like 
vessels, with Nestin in an internal layer. b) Nestin (green) and VEGF (red) 
expression with colocation (yellow) around these vessels. c) LEA (green) 
and CD133 (red) with light colocation (yellow) at some points of the vessels. 
Scale bar= 25 μm. 
a b c 
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We also observed MAP-2 staining around some tumoural vessels. MAP-2 
is not expressed elsewhere inside the tumour, neither in the small 
proliferations (Fig. 31 a), nor in the most malignant gliomas (Fig. 31 b), but 
around some tumoural vessels in the most advanced stages, there is 
sometimes a small layer of cells positive for MAP-2 (Fig. 31 c). These MAP-2 
cells are located externally with respect to the endothelial cells (Fig. 31 d), and 
do not co-express GFAP (Fig. 31 e). 
 
 
 
 
 
 
 
 
 
 
Figure 31: MAP-2 (green) expression in the ENU-gliomas a) There is no 
MAP expression inside the low grade gliomas with GFAP (red) positivity, b) 
in the high grade gliomas MAP is expressed strongly outside the tumour, 
with high VEGF (red) expression and sometimes around mildly aberrant 
vessels like show in c) and d) with MAP expressed around vessels positive 
for von Willebrand Factor (red). e) This Map-2 expression does not co-
locate with GFAP cells around the vasculature (red). Scale bar (a) =1mm, 
scale bar (b-e) =50 μm. 
a b 
c 
d e 
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5.3.4-Border expression of markers related to stem cells 
The border of stage II and III gliomas is another area where we have 
observed stemness marker expression in the ENU-gliomas. There are cells in 
the border that are positive for the Nestin, Osteopontin and Notch-1 markers. 
The Nestin-positive cells (Fig. 32 a) have an elongated morphology with 
many cellular prolongations. Osteopontin expression (Fig. 32 b) is to be seen 
as granules in the cytoplasm of some cells around the border. In the case of 
Notch-1 (Fig. 32 c), cells positive for this marker have a fibre-like (stringy) 
morphology and are abundant in the peritumoural area. 
 
 
There are many cells positive for Nestin that appear isolated at the 
tumoural border in stages II and III (Fig. 33 a, b). These cells have a similar 
morphology to the scattered one found throughout the tumoural mass in the 
early stage (Fig. 33 c). These cells have astrocyte-like morphology, are 
positive for GFAP (Fig. 33 a) and sometimes for VEGF as well (Fig 33 b). 
Osteopontin is also expressed in the border for a subset of cells. Distribution 
of positivity is as lumps inside the cytoplasm and many of the Osteopontin-
positive cells co-locate with GFAP (Fig. 33 c) and VEGF (Fig. 33 d) displaying 
their astrocytic morphology as well. 
a b c 
Figure 32: Immunofluorescence of Nestin (a), Osteopontin (b) and Notch (c) 
in the border area of the tumours. Nestin (a) is expressed in astrocyte-like 
cells with big cellular prolongations. OPN (b) is marked in the cytoplasm of 
many cells in the border and Notch-1 (c) expression is fibre-like 
surrounding the tumour 
Scale bar =50 μm. 
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As previously mentioned, Notch-1 is expressed in the borders of the 
gliomas as a fibrilary expression (Fig. 34 a). It has no relationship with Nestin 
expression (Fig. 34b), or with the vasculature of the border (Fig. 34 c). Notch-1 
and OPN expressions are complementary in the cytoplasm of some cells (Fig. 
34 d). 
 
 
 
Figure 33: Double immunofluorescence of Nestin (green) with VEGF (a, red) 
and GFAP (b, red) and Osteopontin (green) with VEGF (c, red) and GFAP (d, 
red) in the tumoural border. There is some co-location (yellow) of Nestin 
and VEGF around the tumour and a bit less of Nestin and GFAP. OPN 
positive cells co-locate intensely in the border both with GFAP and VEGF.  
Scale bar =50 μm. 
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5.3.5-“Spheroid aggregates” 
Following double immunostaining assays against Nestin and antigens 
like: GFAP, CD133, GluT-1, and VEGF, it has been found that inside the 
spheroid aggregates there are Nestin+ cells, CD133+ cells and 
Nestin/CD133+ cells. The co-expression of Nestin and CD133 can be 
observed in some cells with small size (Fig. 35 c, arrow). Those cells have a 
round morphology with scarce cytoplasm and dense nuclear chromatin.  
GFAP-positive cells are to be seen surrounding the aggregates, as 
though “encapsulating” these cellular aggregates (Fig. 35 b). At the periphery 
Figure 34: Double immunofluorescence of Notch (red) and other markers in 
the tumoural border. a) Notch expression around the border b) Nestin 
(green) does not co-express with Notch, c) Vessels marked with LEA(green) 
does not co-locate with Notch expression, d) Only in OPN (green)/Notch can 
be seen some co-expression of both markers. 
Scale bar =50 μm. 
a b 
c d 
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of these aggregates, and to some extent inside them, there are VEGF+ cells 
and also cells that slightly co-express VEGF and Nestin (Fig. 35 a, arrows). 
Both GFAP and VEGF immunomarkers stain astrocyte-like cells. 
Most of the small aggregates do not have vessels inside them. 
Occasionally, some capillaries immunopositive for GluT-1 were found near 
these shapes (Fig. 35 d, arrow). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: Double immunofluorescence study of stem cell markers 
expression in the spheroid aggregates; Nestin-VEGF (a), Nestin-GFAP (b), 
Nestin-CD133 (c) and Nestin-GluT-1 (d). VEGF (a) only co-locate with 
Nestin in some cellular prolongations, mainly around the Nestin-positive 
cells. GFAP (b) is located externally from the Nestin-positive cells. There are 
some cells co-expressing Nestin and CD133 (c), and it appears that Nestin 
is located a bit farther from the nuclei than CD133. There is no co-
expression of Nestin and GluT-1 in the aggregates (d). Scale bar =25 μm. 
Results                                                                                                                       . 
 - 100 -
Some of the huge aggregates were structures similar to the small ones, 
but bigger in size by having a greater number of cells inside. These 
aggregates also have bigger Nestin-positive cells with prolongations (Fig. 36 
a). In the interior and the periphery of these huge aggregates there are 
occasionally aberrant vessels positive for the BBB marker GluT-1 (Fig. 36 b) 
and also some large Nestin+ cells co-expressing VEGF (Fig. 36 c). 
 
5.3.5.1-Quantitative study 
The quantification of the number of spheroid aggregates (Fig. 37) 
marked with Nestin showed that even though they can appear in the first 
stage (27% of stage I tumours have at least one aggregate), the vast majority 
of them are shown in stage II (when they are found 81% of tumours) and III 
gliomas (in 78% of tumours in this stage). There is an increase in the number 
of spheroid aggregates in the intermediate and advanced stages, compared 
to stage I gliomas. There is a significant difference in the number of them 
between stage I (0.55±0.14; n=28) and stage II (4.455±0.8445; n=22) 
(p<0.0001) and stage III (4.750±1.018 N=28) (p<0.001) (Fig. 37). We also 
measured the density of the spheroids inside these gliomas and observed 
that the highest density appears in stage II (1.102±0.224; n=23). In stage I 
Figure 36: Immunofluorescence staining of the huge cellular aggregates 
marked with Nestin (a), Nestin/Glut-1 (b) and Nestin/VEGF (c). In all images 
can be seen great aggregates of Nestin cells with different shape. Some of 
these aggregates have vessels positive for Glut-1 (b). VEGF is expressed 
greatly outside these huge aggregates (c). 
Scale bar =50 μm. 
 
a b c 
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there is almost the same density (0.9993±0.3351; n=28), but in stage III there 
is a great reduction in the density of the aggregates (0.5410±0.1203; n=31). 
There is only statistical significance between stage II and stage III (p<0.05). 
Finally, the mean areas of the aggregates showed an increase during tumour 
development, without statistically significant differences. In the first stage, 
the area of the aggregates is 17.39 ± 4.73 μm2, n=8, in the intermediate stage, 
29.08 ± 6.99μm2, n=67 while it si 29.94 ± 7.59 μm2, n=134 in the advanced 
stage. 
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Figure 37: Nestin positive cell aggregates quantification A) % of cases in 
each stage show spheroid aggregates. B) Mean number of spheroid 
aggregates in the different stages of glioma growth. They are almost absent 
in the first stage, but the number increases greatly in the second and third 
stage. C) The density of aggregate per mm2 of tumour is highest in stage II 
of glioma development. D) Mean size of the spheroid aggregates, there are 
no significant differences. ***p<0.001. 
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This study has provided useful information about the distribution of 
cells expressing stem cell markers in endogenous gliomas during tumour 
development. 
This study has also helped greatly in order to advance in the 
knowledge of behaviour in animal models of gliomas. The data gathered in 
the homecage systems will help to establish the early diagnosis of gliomas 
in order to prevent animal pain or discomfort as well as to optimise 
experimental designs. 
 
6.1-Behaviour for early diagnosis 
The ENU-model for glioma generation is a chronic model that can be 
very stressful and painful for the rats, therefore we pretend to mitigate rat 
discomfort by preventing the pain and making the early diagnosis of 
tumours easier. This model for glioma induction has the disadvantage of 
the latency time for tumours to arise, but it also has another handicap 
(inherent to most glioma models), which is the identification of the 
tumours, including the low-grade tumours. The results show that weighing 
the animals does not provide enough information about their health status; 
therefore other methods are needed in order to correctly identify the early 
asymptomatic stages of the tumour. For this purpose, we performed a 
continued behavioural monitoring of the rats. This way, we were able to 
observe changes that correlated to tumour growth. We have carried out 
these tests (homecage system and open-field test) from the 4th month 
onwards because previous work carried out in our laboratory showed 
gliomas could appear as early as the 6th month of age (Bulnes and 
Lafuente, 2007). For the behavioural analysis, we have used the data 
obtained in two nights, corresponding to rats’ active period when they are 
awake and more active (Yasenkov and Deboer, 2012). 
The study of the behaviour (analysing parameters like food and water 
intake, distance, % of time moving, exploratory index or rearings) has 
provided us with extensive and valuable data for healthy and glioma-
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developing rats during tumour growth. Comparing the two methods usedin 
this study, automatic monitoring of behaviour with a homecage has proven 
to be a reliable test to detect behavioural anomalies (increase or decrease 
in the measured parameters vs control rats) in the rats prior to physical 
symptoms, while the open-field test (carried out according to our 
performed protocol) did not add additional information over the homecage 
test; in all cases where open-field testing detected an altered parameter, it 
could also be detected the with homecage system. A possible solution to 
this problem could be to increase the frequency of the open-field tests in 
order to increase their sensitivity and to try to identify earlier behavioural 
anomalies. Increasing the number of the open-field tests is also easier 
than the homecage stay, because it is a shorter test and no more cages are 
needed. 
Both tests used in this study are automated tests that allow data to be 
collected from the animal without human manipulation, thus minimizing 
errors and bias. 
 
6.1.1-Behavioural changes of prenatally-exposed rats to ENU 
The General Adaptation Syndrome (GAS) (Fig. 38) (Selye, 1946) seems 
to fit with the response observed in the rats in the ENU model. In this 
model, there are three phases: the alarm reaction, the resistance stage and 
the exhaustion stage. Figure 38 shows the body’s reaction in an individual 
affected by a stressor (it can be either physical or psychological). The line 
represents the level of resistance. In the alarm reaction, there is an 
increase in the adrenaline and glucose levels, and also in the metabolic 
activity and muscle tone. The resistance stage is characterised by having 
an increase in the adrenaline and corticoid levels. This phase can have a 
plateau or not, depending on the strength of the stressor. Finally, in the 
exhaustion stage there is a decrease in metabolic activity and immune 
dysregulation (due to a decrease in neuroendocrine hormones), as 
described by Stojanovich, 2010. 
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The behavioural data collected in the tests we performed follows a 
similar pattern to the general adaptation syndrome. The resistance stage 
would be equivalent to the functional reserve and in this study would vary 
in its duration depending on the malignancy of the tumour, the location etc. 
The exhaustion stage would represent the time frame when the animals 
express their physical discomfort and would correspond to our group C 
rats, which show at least one of the items of the Morton and Griffiths 
welfare scale (1985) and a decrease in the measured parameters. 
 
 
 
 
 
 
 
 
Figure 38: General adaptation Syndrome as described by Selye in 1946. The 
black line represents the general animal status. When something alters the 
welfare of an animal, there is a decrease in the animal health that is rapidly 
counteracted by the animal defence system, generating the resistance 
stage. But the body can not hold in this status forever, and if the alteration 
does not disappear, the animal enters in an exhaustion stage, decreasing 
the animal defences and general welfare. 
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The three groups of ENU-exposed rats that have been identified in the 
results (Groups A, B and C) seem to follow a temporal sequence, as 
observed in figure 39. As previously stated, Group A are rats without 
physical or behavioural symptoms, Group B are rats without physical 
symptoms and an increase in at least one of the measured behavioural 
parameters and Group C are rats that display physical symptoms observed 
with the Morton and Griffith test and a decrease in at least one of the 
measured variables. Many rats started in group A, then they moved to 
Group B and finally they got into Group C, meaning that the Group B would 
be the intermediate point where the rats have behavioural alterations, 
before they show physical handicaps. The changes over time for the 
defined groups are be represented in Fig. 39. 
Figure 39: Rat behavioural groups during tumour growth represented by a 
temporal sequence. The black line represents the mean of the control group 
and the variations vs. ENU-exposed rats. In the Group A (green) there is no 
alteration in their welfare score (measured with the Morton & Griffith table) 
or activity. Group B shows an increase in any of the measured behavioural 
data, but no alteration in the welfare score. Finally in Group C the rats have 
an increase in their welfare score and a decrease in the behavioural data. 
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Group B mean time of appearance (almost 6 months) coincides with 
the timing of tumoural development previously reported for this method 
(Zook and Simmens, 2005) and determines that it would be appropriate at 
this time to establish, via MRI, the type and location of the tumours, 
because rats in this group do not display any physical handicap yet. Also, 3 
rats went from group B to C in the 5th month, 6 in the 6th month, and one in 
the 7th and 8th month. So between the 5th and 6th month of age would be 
the critical age for an early diagnosis of the gliomas in this model. The fact 
that group C has a lower time of appearance than Group B can be 
explained because 42% of the rats in group C appeared during the 4th 
month. Of these rats, 37.5% presented an extracranial. Extracranial CNS 
tumours induced by prenatal exposure to ENU have been previously 
identified as meningiomas and malignant schwannomas (Zook and 
Simmens, 2005). These schwannomas are very malignant, fast progressing 
and appear earlier than the gliomas. More repetitions of the tests (at 
shorter intervals) and an earlier start of the behavioural tests would help to 
establish with higher accuracy the time of appearance of each tumour. 
Group C rats present alterations in parameters linked to mobility, but 
also in metabolic related parameters, like food and water intake. That 
means that when this Group appears, the vital parameters are already 
altered and the general rat’s health status is compromised. 
Animals with “welfare score >0” have a higher variability in the range of 
the parameters than rats with “welfare score=0”. This can be explained 
because in the group “welfare score>0”, there are rats in different states of 
health (including rats with clear physical symptoms), increasing the 
variability of the measured data. The variables that allowed us to observe 
behavioural changes before physical symptoms appeared were mainly 
those related to the activity of the animals, like distance walked or rearings. 
It has been previously reported that measuring the behaviour or the 
locomotive pattern in rodents (Martin and Bateson, 1986; Jansen et al., 
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1995) could help to identify the general adaptation syndrome and/or 
prevent animal discomfort. Our results point in that direction. 
 
6.2-ENU-induced glioma incidence and classification 
ENU prenatal injection has become a well-known method to obtain 
gliomas since it was first reported in the 60s (Druckrey et al., 1966). 
The data obtained in this study corroborates previous studies that 
show the induction of several types of CNS tumours, such as different 
grade gliomas, meningiomas and schwannomas (Mennel et al., 2004, Zook 
and Simmens, 2005). 
The incidence (almost 100% of the rats develop a CNS tumour) is 
similar to that previously reported in the literature (Bulnes-Sesma et al., 
2006) and the tumoural development occurs as the rats grow, in the same 
way as human gliomas. This fact allows a closer look into tumoural 
development that other models, such as tumour xenografts, cannot offer. 
The fact that we have observed that intracranial extraaxial tumours 
have the shortest life expectancy coincides with their related malignancy 
(Zook and Simmens, 2005). It also means that the malignancy of ENU-
induced tumours is related to the rat’s age, with the most malignant 
tumours developing as the rats get older. On the other hand, rats with 
post-mortem identified stage III gliomas were rats with the greatest age, 
despite having the most malignant tumours. This can be explained by the 
long time that gliomas take todevelop after ENU exposure and that in this 
model, gliomas become malignant over time. 
The classification of CNS tumours after the ENU exposure, and 
particularly of the gliomas, corresponds with previous studies with this 
model (Zook et al., 2000). Gliomas usually start as small proliferations 
resembling oligodendrogliomas that acquire malignant characteristics like 
necrosis, haemorrhages or diffuse borders as they develop (Fig. 13). The 
tumoural malignancy increases slowly with time and provides tumoural 
vasculature that evolves at the same time as the gliomas. That is a great 
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advantage over fast growing glioma models, which lack of histologically-
acute vasculature (Fomchenko et al., 2006). Our classification for the ENU-
induced gliomas relies on histopathological features of the tumours, but it 
also bears in mind the size of the neoplasias. Stage I tumours are small 
proliferations of cells that never become large enough to displace 
neighbouring structures. On the other hand, stage III gliomas are usually 
big tumours that often occupy a whole hemisphere. 
MRI can detect the CNS tumours, but there are procedural difficulties 
(money and time lost transporting the animals to another city where the 
MRI device is) that hinder the temporal resolution, so we came up with the 
idea of monitoring possible behavioural changes of the rats as a non-
invasive method to identify the ENU-induced tumours. With the present 
data, it is difficult to evaluate the relationship between behavioural data 
and glioma development and future work should be targeted in this 
direction in order to correctly identify the glioma stage before the animal is 
sacrificed. 
 
6.3-Stemmness markers in ENU-induced gliomas 
The presence of CSCs has been previously described in human 
glioblastomas and also in animal models (Dahlstrand et al., 1992; Singh et 
al., 2003). Nowadays there are many studies about the role of stem cells in 
GBM, for example they have the capacity to initiate tumours (Hadjipanyis 
and Van Meir, 2009), and may be responsible for a high in vitro migration 
capacity and high in vivo infiltration capacity (Yu et al., 2011, Calabrese et 
al., 2007; Sadahiro et al., 2013) as well as higher levels of hypoxia 
resistance (Seidel et al., 2010). But little is known about the distribution of 
cell aggregates that we have called “spheroid aggregates” (Fig. 22) inside 
the tumour or their participation in the early forms of gliomas. 
There are few published studies of the presence and distribution of 
stem cells in low-grade gliomas. For this purpose, animal models are an 
important tool for studying these tumours, because they allow performing 
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studies throughout the developmental process. The endogenous 
generation of CNS tumours via transplacentary administration of ENU in 
rats during pregnancy has been widely documented and is a well-known 
and reliable model to study gliomas in different stages (Zook and 
Simmens, 2005; Bulnes-Sesma et al., 2006). The early tumours are small 
masses of cells resembling classic oligodendroglioma. The most 
malignant forms show areas of necrosis and pseudopalisades, like 
anaplastic oligodendrogliomas or glioblastoma multiforme. In fact, this 
model has been previously used to research many cellular, biological and 
genetic aspects of gliomas, (Jang et al., 2004; Jang et al., 2006; Bulnes et 
al., 2011). However, it has not been used to study the presence and 
distribution of immunopositive cells for stemness markers during tumour 
growth. 
Despite numerous studies about the tumoural stem cells presence in 
gliomas, there is still controversy about the identification potential of these 
markers. Nestin remains questioned as a CSC marker, because it is a 
neural lineage undifferentiation marker expressed in the brain at the 
hippocampus and the SVZ in rats (Nogueira et al., 2014). Nestin is also 
overexpressed in areas of active neurogenesis after brain injury (Holmin et 
al., 1997; Michalczyk and Ziman, 2005) and it has been used to label 
immature brain endothelium (Matsuda et al., 2013). In the ENU-glioma 
model, the perivascular Nestin-positive cells (Fig. 29, 30), the closest ones 
to the endothelium, resemble pericytes. There are few studies about Nestin 
expression in pericytes (Birbrair et al 2014); though there are some 
examples of these cells playing a relevant role in tumoural vasculature 
(Cheng et al., 2013) and being present in the perivascular stem cell niche 
(Brooks et al., 2013). Although Najbauer and collaborators observed both 
Nestin+ cells and pericytes around tumoural vasculature in a xenograft 
model of glioma, they stated that there is no co-location of Nestin and 
pericyte-associated markers (Najbauer et al., 2012). The main challenge in 
order to definitely identify these Nestin-positive cells as pericytes is the 
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lack of specific markers for pericytes (Armulik et al., 2011); yet Birbrair and 
collaborators claim that there is a subpopulation of pericytes positive for 
Nestin and NG2 and that this subtype of pericytes plays an important role 
in tumoural angiogenesis. However, it is controversial to assure that fact 
since NG2 has been previously used as a marker for immature 
oligodendrocytes (Kang et al., 2010) and an NG2 subpopulation of 
oligodendroglial precursor cells has also been described to be responsible 
for the tumourigenesis in ENU-gliomas (Briançon-Marjollet et al., 2010). In 
order to clearly evaluate whether the perivascular Nestin+ cells are 
pericytes or not, further studies with electron microscopy would be 
necessary to closely examine the location and morphology of these cells. 
The use of CD133, despite being the most used marker for the 
identification of tumour stem cells, is also controversial. Recent research 
points to CD133 as a marker related to a bad survival rate in GBM, rather 
than to stemness (Olausson et al., 2014). Some studies claim that CD133 
is only expressed in gliomas with small round cell morphology with 
hyperchromatic nuclei (Schittenhelm et al., 2011) or under stress 
conditions (Griguer et al., 2008). Other studies propose that CD133- cells 
(apparently non-CSCss), can give rise to tumours (Ogden et al., 2008) and 
to CD133+ cells in specific conditions (Wang et al., 2008), so CD133 
expression would also depend on the microenvironment or culture 
conditions. This debate around the suitability of CD133 marker expression 
as a cancer stem cell (CSC) marker could be partially explained by the 
plasticity model. According to this model, the stemness status in the 
tumours is not a definitive status and is driven by the environment around 
the cells. Thus, CD133-negative cells could adapt to hostile environments 
and transform themselves into CD133-positive cells, capable of generating 
a tumour. 
 
Presence and prevalence of stem cell markers in tumours have been 
previously used as a prognostic factor, mainly through quantification of the 
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expression of Nestin, CD133 and Osteopontin in humans and animal 
models (Jang et al., 2006; Zhang et al., 2008; Zeppernick et al., 2008). 
Accordingly, an increasing expression of any of these markers is described 
as a bad prognostic factor. Specifically, Nestin expression increases with 
glioma malignancy (Ehrmann et al., 2005, Shin et al., 2013). 
Our data demonstrates that the number and the size of the spheroid 
aggregates increases in the malignant stages of the ENU-gliomas, 
supporting the hypothesis of of Nestin+ aggregates as a bad prognostic 
factor. 
This study also shows how the cellular Nestin expression gets 
increased in relationship with markers of proliferation, like BrdU and Ki-67 
and it suggests a relation between those markers. Both BrdU and KI-67 
expression have been related to the degree of malignancy and are linked to 
a bad prognosis. Further studies about the link between stemness markers 
(Nestin among others) and proliferation should be performed, in order to 
research their relationship (Johanessen and Torp, 2006). 
 
6.3.1-Perivascular expression of stem cell markers 
Previous work from our group has described the adaptations of the 
vascular network during glioma development and how the vessels acquire 
aberrant morphologies that provoke an irregular blood flow (Bulnes et al., 
2009). In the ENU-induced glioma model, we have also observed how VEGF 
has different patterns of expression during glioma malignancy (Bulnes et 
al., 2007): in the low-grade gliomas there is a low level of VEGF expression, 
increasing hugely in the intermediate stage, the so-called “angiogenesis 
switch”. This stage is defined as an alteration in the balance between pro- 
and anti-angiogenic factors (Baeriswyl et al., 2009). Our results show that 
Nestin- and CD133-positive cells are found inside the ENU-induced 
gliomas in different perivascular locations. In the neoangiogenic tumoural 
border Nestin and CD133+ cells are found to co-locate with GFAP and 
VEGF around the glomeruloid vessels forming “perivascular niches”. The 
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glomeruloid vessels have been reported as a characteristic mark of GBM 
(Kleihues et al., 2002) and they have been found to express VEGF (Brat and 
van Meir, 2001). Furthermore, the glomeruloid tufts are thought to be 
created after a response to VEGF secreted by hypoxic conditions (Brat and 
van Meir, 2001) while, in the hypoxic interior of the tumour, Nestin and 
CD133+ cell aggregates appear located close to tortuous and dilated 
vessels (forming also the perivascular cluster) (Fig. 29). 
The perivascular distribution of CSCs has been previously reported (He 
et al., 2012) and it is composed of Nestin positive cells (Calabrese et al., 
2007) along the vessels, with clusters of CD133+ cells close to the vessels 
(Christensen et al 2008), among other markers such as Notch-1 and iNOS 
(Filatova et al., 2012). Neural stem cells have been confirmed to appear in 
vivo in vascular niches, as the endothelial cells provide a favourable 
environment for them (Shen et al., 2008; Gomez-Gaviro et al., 2012), and do 
CSCs also appear in vivo (Calabresse et al., 2007; Borovski et al., 2009). 
The endothelial cells have been proposed to increase the protection of 
tumour stem cells against radiotherapy in the perivascular 
microenvironment (Garcia-Barros et al., 2003) by absorbing most of the 
radiation damage, so they are also important in the regulation of the niche. 
Our results corroborate the existence of a perivascular cluster of cells 
positive for Nestin and CD133 (and sometimes co-expression of both 
markers), but in our results we have not seen spheroid-like structures of 
these markers around the tumour vasculature. The role of CSCs in 
tumoural angiogenesis has been previously reported (Bao et al., 2006; 
Folkins et al., 2009), and the presence of Nestin/VEGF co-expressing cells 
in the intermediate and advanced stages would support this model. Thus, 
our results support a model where Nestin and/or CD133 positive cells 
would trigger angiogenic stimuli when the tumour needs to increase its 
nutritional demand (Bulnes et al., 2009). 
This hypothesis of the perivascular cells being highly responsible for 
the process of tumoural angiogenesis is supported by the expression of 
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angiogenic factors like VEGF, among others. It has been stated that CSCs 
in a hypoxic environment produce HIF-2 alpha that induces the production 
of VEGF (Heddleston et al., 2009; Heddleston et al., 2010). Angiogenesis 
would be driven in the tumoural interior mainly by Nestin/CD133 positive 
cells placed around the aberrant vessels. Some of these cells may express 
one or both stemness markers. 
Mildly abnormal vessels express BBB markers like GluT-1 or EBA. 
Glucose transporter 1 is developed very early as a basic system for the 
nutrition of cells and it can also be seen around very aberrant vessels. In 
opposition, EBA belongs to a more evolved system specific of the brain 
endothelium that disappears in glomeruloid vessels. 
The only place where we have observed light co-location of CD133 
and LEA in any tumoural stage is around the glomeruloid vessels, 
supporting the hypothesis of cellular transdifferentiation in tumours (Zhao 
et al., 2010; Soda el al., 2011; Scully et al., 2012). These studies 
hypothesise that cancer cells (and CSCs) can give rise to endothelial cells 
in vivo or mimic vasculature in vitro. Specifically in gliomas, it has been 
proposed that CD133+ cells can give rise to tumour endothelium (Wang et 
al., 2010). 
On the other hand, CD133 is also known for being positive for 
endothelial precursor cells (EPCs). EPCs are a very small portion of 
circulating blood cells with the ability of differentiating to endothelial cells. 
EPCs have been characterised by being positive for CD34/CD133/VEGFR-2 
(Xiao-Qin et al., 2014). It has been reported that EPCs are recruited into 
certain tumours and take part in the neoangiogenesis process (Xiao-Qin et 
al., 2014). Although there is currently no data showing EPC involvement in 
angiogenesis in gliomas, an increase in EPCs has been described (detected 
with the previous mentioned antigens) in peripheral blood (Rafat et al., 
2010). 
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So it is difficult to say if the CD133 positive cells in our ENU-gliomas 
are tumour cells or EPCs, as more investigation should be carried out in 
order to explain their origin. 
MAP-2 is a major component of the cytoskeleton and is expressed in 
neural differentiated cells (Liu et al., 2003). Nevertheless, its expression 
has also been observed in many neoplasms such as small cell carcinoma, 
medulloblastoma and some breast tumours. Following our MAP-2 
expression results, the perivascular cell MAP-2 expression observed in 
ENU-gliomas has been previously reported in human astrocytomas 
(Wharton et al., 2002), oligodendrogliomas (Blümcke et al., 2001) and in 
some glioma cell lines (Shiras et al., 2003). In human studies, 
cytoplasmatic MAP-2 expression has been described, both in isolated cells 
or forming a perivascular pattern (Wharton et al., 2002), in the same way as 
we have also observed in the ENU-induced gliomas. Messam and 
collaborators reported that a small fraction of Nestin+ cells during CNS 
development that are also positive for MAP-2 (Messam et al., 2000), but 
further studies are needed in order to decipher the potential role of MAP-2 
in gliomas and cancer stem cells. 
Even though MAP-2 is not a stemness marker, its expression has been 
observed in Nestin+ cells (Messam et al., 2000) and MAP-2 cDNA 
expression has been reported in some neurospheres (Suslov et al., 2002), 
in part due to the heterogeneity of stem cells. 
 
6.3.2-Stemness marker expression in the tumoural border 
Osteopontin expression in glioma models (Jang et al., 2006), has been 
described as a bad prognostic factor, even though some authors claim that 
a high OPN expression correlates with higher survival in animal models, as 
OPN is related with a decrease in cellular migration (Selkirk et al., 2008). 
OPN expression is related to Nestin and VEGF expression in the tumour 
border (Takano et al., 2000); therefore this is found sometimes around 
vessels but mainly in the tumoural border. We have found an increase in 
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OPN+ cells in the tumoural border in the advanced gliomas. Previously it 
has been reported that OPN overexpression induces angiogenesis (Wang 
et al., 2011) and cellular migration in glioma cells in vitro (Lu et al., 2012), 
so the border OPN expression in the present study could be related to 
angiogenesis and tumoural migration. 
Cells expressing Nestin at the border have the morphology of well-
differentiated astrocytes that co-express GFAP and VEGF (Fig. 33), so most 
probably these Nestin-positive cells would be astrocytes involved in 
tumoural border angiogenesis. VEGF expression at the border has been 
previously reported both in isolated cells and in perivascular cells around 
the vascular glomeruloids, typical of the most malignant gliomas (Brat and 
Van Meir, 2001). 
Notch-1 is a factor needed for stem cells renewal (Matsuda el al., 
2013) and its expression in glioblastomas has been previously described 
as a factor that enhances stem-like properties (Charles et al., 2010) and 
radio resistance (Wang et al., 2010 b). As previously observed in Fig. 33 d, 
OPN and GFAP co-locate in the cytoplasm of astrocyte-like cells in the 
tumoural border and we have also observed that OPN and Notch-1 are co-
expressed complementarily in some cells of the tumoural border. Notch-1 
has been strongly related to the astrocytic differentiation process (Tanigaki 
et al., 2001), so it could explain the Notch-1 expression in this study. 
We have observed an increase in Notch expression around the border 
zone mostly in the malignant gliomas. Similarly, we have observed 
Nestin/CD133 expression (mainly around the aberrant glomeruloid 
vasculature) in the tumoural border. Notch signalling has been linked with 
angiogenesis (Li and Harris, 2009) and it becomes up-regulated in glioma 
vasculature (Li et al., 2007). It has been reported that Notch signalling can 
directly up-regulate Nestin in human gliomas (Zhang et al., 2008), thus the 
Notch expression in the tumoural border zone. Notch-1 expression in our 
study does not co-express with Nestin positivity, so it is more probable 
that Notch-1 expression could be related to the angiogenic border. Notch-
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1 has also been related to hypoxic conditions (Gustafsson et al., 2005) and 
to the stem-like phenotype, promoting the self-renewal of glioma-derived 
CSCs and inhibiting their differentiation (HU et al., 2011). 
 
6.3.3-Spheroid aggregates of Nestin positive cells 
These spheroid clusters are defined as limited areas in the tumour 
with cells positive for Nestin and CD133 and similar morphology to in vitro 
stem cell morphology growth. 
The spheroid aggregates in the ENU-induced gliomas appear in the 
first stage (Fig. 37) of glioma development (classic oligodendrogliomas), 
but it is not until the intermediate stage that these aggregates appear in 
greater numbers. Further studies should be undertaken to determine 
wheter they have a relation with the “angiogenesis switch”, which happens 
around the same stage and is the moment when an overexpression of pro-
angiogenic factors begin to appear (Bergers and Benjamin, 2003). We have 
observed that “spheroid aggregates” show many parallelisms to tumour 
neurospheres, such as cell morphology, (small and round with dense 
nuclei and without cellular prolongations), immunomarker expression 
(Nestin, CD133, GFAP), etc (Bez et al., 2003; Pavon et al., 2014). 
Neurospheres have also been isolated from human and animal model 
gliomas and show Nestin/CD133 positivity (Singh et al., 2003; Bexell et al., 
2009), as well as Sox-2 (Brazel et al., 2005) and even GFAP (Jensen and 
Parmar, 2006), but this GFAP expression appears mainly in the most 
differentiated cells of the exterior of the neurospheres. Tumourspheres 
(from CNS tissue) and neurospheres (from the SVZ) are also similar to 
each other (Vik-mo et al., 2011) and only differ in nuclear morphology, the 
tumourspheres having more nuclear atypias and expression of some 
markers like β-III-tubulin. So, the spheres from cancer and neural stem 
cells are comparable. 
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As previously stated by Pastrana and collaborators (Pastrana et al., 
2011), the gold standard assay to identify stem cells is the in vitro sphere 
growth. Protocols vary substantially between different assays, but in all of 
them, a restrictive medium and preventing the cells to adhere to the plate 
are necessary conditions to induce the stem cells to form spheres. So the 
CSCs could form spheres in vitro in order to protect themselves against 
adverse conditions such as absence of nutrients. In the same way, we 
hypothesise that Nestin and CD133 positive cells in vivo, in the ENU-
induced tumour model, could form the spheroid aggregates to protect 
themselves against hypoxia, lack of nutrients or maybe also 
chemotherapeutics (Bao et al., 2006; Rich, 2007; Denysenko et al., 2010). 
In addition, these arrangements could represent a cell aggregate 
proceeding from a single cell clone (Pastrana et al., 2011), formed before 
the cells begin to spread. The cells in the spheroid aggregates could 
stimulate cells around them to produce angiogenic factors in order to 
escape from the adverse conditions. Similarly, we have frequently 
observed VEGF-positive cells around the spheroid arrangements. The 
encapsulation of these structures by VEGF and GFAP positive cells would 
also serve to isolate the cells inside and provide them with a favourable 
microenvironment. 
The spheroid clusters in this model form the necessary 
microenvironment for the stem cells’ maintenance and development. It has 
been previously proposed that niches of stem cells could act as a reservoir 
(Christensen et al., 2011) and could be responsible for the high rate of 
relapse of malignant gliomas, and this could be done by the spheroid 
aggregates. In the ENU-gliomas, we observed that the mean size of 
spheroid aggregates increased with malignancy. It has been reported that 
even though the in vitro size of tumourspheres varies greatly, between 40-
150μm (Pastrana et al., 2011), it is possible to culture huge neurospheres 
with 300 or even 400μm of diameter under certain conditions (Mori et al., 
2006); in the same way we could observe some huge spheroid aggregates 
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in the most malignant gliomas (Fig. 36). Therefore, our data supports a 
model where aggregates of Nestin/CD133+ cells would act as a reservoir 
of immature cells, protected by a layer of more differentiated astrocyte-like 
cells. 
 
6.4-Future perspectives 
Research into glioma stem cells in recent years has provided a lot of 
information about the mechanism of stemness in gliomas and all the 
consequences they have in tumour growth, angiogenesis and treatment. 
As a result of these efforts, some methods have already been proposed to 
selectively attack CSCs in vitro and in vivo (Bao et al., 2008, Gil-Ranedo et 
al., 2011). 
Nevertheless, early diagnosis of the tumours is also critical, both in 
humans and in animal models). Research into behavioural characterization 
is becoming increasingly important, so as to prevent animal pain and 
discomfort and to provide cheaper and non-invasive diagnostic methods. 
 
6.4.1-CSCs in the future of GBMs 
Further research is needed to elucidate the exact role of these 
spheroid aggregates and to better understand their parallelism to the 
neurospheres. However, future perspectives of the advantages of 
identifying the spheroid niches as an in vivo approximation of the 
neurospheres would include the non-invasive identification of the 
“spheroid aggregates” to unveil their distribution and the possibility of 
targeting them in order to attack the most malignant cells in the tumour. 
If the spheroid aggregates in the ENU-model were really neurospheres 
analogues, this would open up new ways to research the neurospheres’ 
behaviour in vivo and in vitro, and the relation with other structures like 
tumoural vasculature. 
Therefore, the ENU-induced tumour model could provide helpful 
information to aid understanding the nature of tumoural stem cells and 
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study their properties. An in vivo characterization would be the first step 
for a proper identification, giving raise to guided therapies against these 
cells, as they are the ones that lead the tumourigenesis and angiogenesis 
processes. 
 
6.4.2-Behaviour as a future diagnostic tool 
Behaviour and metabolic alterations measured through continued 
monitoring can be used for an early diagnosis tool before the animals 
display any physical handicaps. This method provides a non-invasive way 
to identify gliomas (and potentially other pathologies) and at the same 
time, prevents and reduces animal pain. In order to correctly achieve that 
aim in the future for gliomas and other pathologies, it is necessary to know 
the normal behaviour of the animal studied and the alterations that the 
animals suffer during glioma development, as we have accomplished in 
this study. 
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1.-The ENU-induced glioma model provides endogenous tumours that 
allow the study of neoplastic growth and their microenvironment from the 
early stages. 
 
2.-Diagnosis through clinical signs and changes in behaviour is a non-
invasive method that provides useful information about tumoural 
development, but no consistent correlation with the severity of tumours 
was found. However, the information allows a significant improvement in 
the animal welfare. During the continued monitoring, distance run was the 
most significant parameter to detect alterations before the apparition of 
symptoms. 
 
3.-Repeated monitoring of rats in a homecage system is a useful way to 
detect changes in the clinical state suggesting the presence of a CNS 
tumour before devastating physical consequences appear. Open-field 
testing does not provide extra information about the rat’s welfare, but 
confirms the suitability and reliability of data obtained by the homecage 
system. 
 
4.-Nestin expression is present from the earliest stages of glioma and its 
expression increases during development. Nestin+ cells show different 
morphologies and a small fraction of them are small round cells with 
scarce cytoplasm, like the stem cell morphology. On the other hand, CD133 
is only immunodetected in the most malignant stages. 
 
5.-Cells expressing various stemness markers are distributed throughout 
the heterogeneous tumour mass identifying three different tissue areas:  
the tumoural border, the perivascular region and the interior of the glioma. 
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6.-In the tumoural border, there are many cells expressing Nestin and 
Osteopontin that are big and morphologically well differentiated and co-
express GFAP and VEGF, suggesting their involvement in border 
angiogenesis. 
 
7.-Numerous perivascular cells are positive for Nestin and CD133. This 
expression appears around aberrant vessels, being highest around 
glomeruloids, where slight co-location with VEGF is frequent. 
 
8.-This model shows arrangements of cells positive for Nestin and CD133, 
which we have named “spheroid aggregates”. The most undifferentiated 
cells are present inside these formations with a small and round 
morphology without prolongations. Spheroid aggregates are surrounded 
by VEGF/GFAP+ cells and as a whole resemble the in vitro cell 
arrangements named neurospheres. 
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